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Abstract 
Regenerative medicine has the potential to establish or restore normal function in defective 
tissues and organs. The realisation of such therapies is restricted due to costs, lack of 
scalability and inefficient manufacturing process controls. A major contributor to cost is the 
use of expensive growth factors supplemented into media at high concentrations.  
In vivo, growth factors exist in soluble, immobilised and transmembrane forms, expressed in 
a spatiotemporal fashion within the stem cell niche. In comparison to soluble equivalents, 
immobilised growth factors exhibit increased potency, distinct functional activities, 
improved cell phenotypic control and act in synergy with other soluble and immobilised 
ligands. To date, most research into immobilised growth factors has been restricted to 
planar cell culture surfaces such as tissue culture plastics which have limited scalability.  
To address the scalability limitations, a novel growth factor immobilisation technology was 
developed using magnetic microparticles which can be scaled with respect to surface area 
to volume ratio in standard stirred tank bioreactors. Three clinically relevant growth factors, 
SCF, TPO and GM-CSF were immobilised and were shown to remain functionally active 
where surface concentration could be manipulated in a number of ways. Through a series of 
experiments, it was demonstrated that immobilised growth factors exhibited ~10-fold 
increase in potency compared with soluble equivalents and remain stable for up to 192 
hours following recycling during multiple media passages. Immobilised growth factors were 
able to expand more cells over a longer period of time after transient exposure and finally, 
the immobilisation technique was successfully applied to the expansion of umbilical cord 
derived haematopoietic stem cells using immobilised SCF. 
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The immobilisation method described here has the potential to significantly reduce media 
costs in large scale cell manufacturing processes. 
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1 Introduction 
Regenerative medicine is an umbrella term for therapies which may involve molecular 
therapy, gene therapy, stem cell transplantation, tissue engineering and reprogramming of 
cell and tissue types or a combination thereof[1]. Due to the broad spectrum of therapies 
involved in regenerative medicine, attempts at defining regenerative medicine have led to 
lengthy and ambiguous definitions however, in 2008 a brief definition was published; 
“Regenerative medicine replaces or regenerates human cells, tissues or organs, to restore or 
establish normal function”[2]. Regenerative medicine is often considered the pinnacle of 
21st century medicine due to its potential to restore or establish function in disorders where 
traditional pharmaceuticals have failed to deliver.  
1.1 Cell and Gene Therapies 
Cell therapies consist of the transplantation of cells with therapeutic potential. Often these 
cells are stem cells which can reconstitute a defective organ or tissue in order to restore or 
establish normal function, but they can also involve more specialised cells such as T-cells. In 
addition the transplanted cells can be genetically modified to correct for inherited genetic 
disorders such as Sickle Cell Anaemia.  
1.1.1 Cell Therapies 
A stem cell can be defined as a cell that has the capacity to self-renew and has the potential 
to produce differentiated progeny with more specialised function or a more mature 
phenotype[3]. Patients can be treated with their own stem cells (autologous) or by donor 
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stem cells (allogeneic treatment). Both types of treatments have benefits and risks as 
summarised in  Table 1.  
 A summary of benefits and disadvantages of Autologous and Allogeneic stem cell treatments. Table 1.
Benefits Risks 
Autologous Allogeneic Autologous Allogeneic 
No GvHD Off-the-shelf 
product. 
Higher 
manufacturing costs 
[4] 
Potential for GvHD 
and or pathogen 
transfer. 
 Scalable. Delayed treatment 
time 
 
 Quicker release due 
to pre-approved QC 
Variability between 
patients due to stem 
cell quality 
 
 
Despite the benefits associated with allogeneic therapies, the risk of Graft versus Host 
Disease due to HLA mismatches is a major challenge for the adoption in clinical settings. 
1.1.2 Gene Therapies 
The origins of gene therapy can be traced back to 1928 where Frederick Griffith’s 
demonstrated the principle of genetic transformation of pneumonia from a non-virulent 
form to a virulent form. It wasn’t until 1962 that the first documented gene transfer in 
mammalian cell lines was reported and in 1989 the first gene transfer into humans took 
place [5].  
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Gene transfer can be achieved using viral and non-viral vectors, the most common vectors 
being adenoviruses, retroviruses and naked plasmids (non-viral) which are reviewed 
elsewhere [6].   
Gene therapies can be combined with cell therapies, for example where the host cell for the 
gene construct is transfected to become stem cells which have the ability to reconstitute 
entire tissues with cells expressing normal function (i.e. Strimvelis™, GSK). 
1.1.3 The Cell and Gene Therapy Landscape 
Some recent successes for the industry include a gene therapy for ADA-SCID patients 
(Strimvelis™, GSK), which has been granted market approval by the European Medicines 
Agency (EMA) and will cost around 594,000 euros per patient. Cell and gene therapy for 
immuno-oncology targets (particularly for CD19 malignancies) have many promising 
products in late stage clinical trials (e.g. Juno Therapeutics, Bluebird Bio, Kite Pharma, 
Celgene). 
Cell and gene therapy start-ups and small-medium sized enterprises (SMEs) have achieved 
some of the biggest IPOs in recent biotech history (BlueBird Bio $101 Million, Kite 
Therapeutics $127 Million, NantKwest $207 Million). The Alliance for Regenerative Medicine 
estimates public and private companies have raised $10 Billion in 2015 with over 70 
treatments in late stage clinical trials. Significant investments and collaboration between 
industry and academia are key to moving the field forward.  
The safety of cell and gene therapies particularly with T-cell engineered therapies is a real 
concern for the industry. In March 2017, it was reported that there were multiple deaths 
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associated with the infusion of T-cell engineered constructs in a pivotal trial from Juno 
Therapeutics (JCAR-015).  
1.1.4 Clinically Relevant Cells 
Multiple cell types are being investigated in the clinic for cell and gene therapies, with the 
majority being Haematopoietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), T-cells 
(CAR T-cells and or TCR T-cells) and induced pluripotent stem cells (iPSCs). Cells can be 
classified by their differentiation potential: 
• Totipotent - A cell that has the capacity to develop into any type of human cell. An 
example is a Zygote. 
• Pluripotent – A cell that can differentiate into all three germ layers. Examples are 
embryonic stem cells or iPSCs. 
• Multipotent – A cell that can develop into more than one type of cell but does not 
have the potential to differentiate into all types of cells. Examples are HSCs and 
MSCs. 
• Unipotent – has the capacity to develop into one cell type. Examples are 
Hepatoblasts.  
A brief overview of common cell types for cell and gene therapies are given below however, 
the focus of this thesis will involve HSCs since they are the most widely characterised and 
utilised cells in transplant settings.  
1.1.4.1 Mesenchymal Stem Cells  
Mesenchymal stem cells (MSCs) are adherent cells capable of tri-lineage differentiation into 
bone, cartilage and adipose tissues derived from the perivascular niche. Therefore, MSCs 
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suited towards musculoskeletal indications. Recently MSCs have been shown to exhibit 
immuno-modulatory properties (by the secretion of anti-inflammatory paracrine factors) 
making them suitable for immune disorders such as Crohn’s disease and other inflammatory 
bowel syndromes [7]. MSCs have also demonstrated repair of cardiac function following 
myocardial infarction [8].  
1.1.4.2 Induced Pluripotent Stem Cells    
The pioneering work conducted by Shinya Yamanaka’s lab in 2006 showed that adult stem 
cells could be reprogrammed into pluripotent stem cells by genetically engineering the cells 
to express four transcription factors; oct4, sox2, cymyc and klf4[9]. The work has the 
potential to revolutionise allogeneic therapies where the donors own stem cells are not of 
adequate quality for cell therapies. However, safety concerns have arisen with the 
formation of tumours in multiple independent studies [10]. A recent pivotal clinical trial for 
wet age-related macular generation (AMD) has been put on hold because mutations were 
observed in transplanted cells (Rikagaku Kenkyūsho Institute, Japan).  
1.1.4.3 T-Cell Therapies 
T-cell therapies may comprise genetically engineered and expanded T-cell populations with 
modified T-cell receptors (TCR) or chimeric antigen receptors (CAR) and are mainly utilised 
to target clinical indications involving liquid or solid tumours. Naive or central memory T-
cells are thought to correlate with long-term activity and increased anti-tumour activity in 
pre-clinical models[11], [12]. 
Both CAR and TCR T-cells have shown clinical efficacy since the first proof of concept studies 
in 2005 [13]. The main differences between CAR and TCR cells are summarised below 
in  Figure 1. 
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Despite many clinical trials taking place globally with TCR and CAR therapies, off-target toxic 
effects continue to restrict the progression of the therapies into the clinic. Recently, a 
leading candidate was withdrawn from Juno Therapeutics’ pipeline due to several patient 
deaths in their Rocket clinical trials (JCAR015).  
Advances are being made to improve safety of t-cell therapies with next generation 
therapies having suicide switches’ so that implanted cells can be killed in a short period of 
time should any untoward toxic side-effects occur[14]. Such advances will inevitably 
accelerate therapy development.   
 
 Figure 1. The differences between CAR and TCR therapies. TCR cells recognise antigens presented by 
MHCI molecules and are therefore HLA specific cells. CAR cells recognise cell surface antigens and 
generally cannot recognise intracellular tumour antigens. Image modified from [15]. 
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1.2 Haematopoietic Stem Cells 
HSCs (or CD34+ cells) were first shown to have colony-forming potential in in vitro cultures 
and were later shown to have the capacity to repopulate immunocompromised mice [16], 
[17]. Today, over 42,000 HSC transplants take place every year, with the majority being 
performed to treat haematological malignancies [18]. More recently, HSCs have also been 
used as a ‘host cell’ for genetic engineering to successfully cure genetic disease such as ADA-
SCID and sickle cell anaemia [19], [20]. 
Haematopoietic stem cells (HSCs) have the capacity to differentiate into all mature blood 
cell types, through a process known as haematopoiesis ( Figure 2). Haematopoiesis occurs 
throughout the entire human life-span, where cell lineages are directed by a complex 
interaction of physicochemical and biological cues.  
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 Figure 2. A schematic of haematopoiesis showing the lineages produced with different cytokine 
combinations. Image taken from [21] 
1.2.1 Characterisation 
Characterisation of HSCs is difficult due to their complexity, plasticity and lack of sensitive 
characterisation assays. Immunophenotyping using flow cytometry is the most widely used 
method for characterisation, but is usually limited to 7-8 cluster of differentiation (CD) 
markers with standard equipment due to optic limitations (i.e. spill-over of fluorescence into 
other channels). Emerging equipment such as Mass Cytometry can increase those numbers 
of markers to 50+ with the use of radioactive CD tags. With increasing marker numbers; 
tools such as Spanning tree Progression of Density normalised Events (SPADE) become 
important in visualising high-dimensional data and automatically organising cells into 
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hierarchies of related phenotypes. SPADE is increasing our understanding of haematopoiesis 
and cancer biology[22].  
CD markers remain the preferred method for phenotypic identification of cells using flow 
cytometry. Over 30 years ago, cells with ‘repopulating activity’ were identified by expression 
of the CD34+ marker, which remains the most common method for identifying HSCs 
today[23]. Since the discovery of CD34+, many more markers have been identified based on 
their short term or long term repopulating activity[24]. A sub-population of CD34+ cells 
expressing little or no CD38 were identified with extended self-renewal activity [25]–[27]. 
Whereas, some of the most primitive (and rarest) HSCs have been found to express CD133 
[24].  
‘Definitive’ HSCs can be identified by expression of a large combination of CD markers, for 
example CD34+/CD38-/CD90+/CD45RA-/CD49f+/Rho123low/Lin- [28]. Markers such as CD49f 
may be more representative of those cells with good engraftment potential due to its 
involvement in niche homing. Large marker combinations become limited by the optic 
configuration of most modern day flow cytometers (due to fluorescence spill-over into 
detector channels). Simplified marker panels have been proposed such as SLAM markers, 
CD150, CD244, and CD48 and may be more appropriate for phenotypic analysis[29].  
Despite the complexities involved in HSC identification, it is widely accepted that CD34+, 
CD34+/CD38- or CD133+ cells incorporate the stem cell/progenitor HSC populations.   
Genetic profiling amongst various stem cells has highlighted genes upregulated in stem 
cell/progenitor populations including STAT and c-myc genes. Furthermore biochemical 
analysis (for example ALDH) shows increased expression in stem cells, and may be a marker 
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for stem cell quality and engraftment success [30], [31]. A summary of marker expression 
throughout haematopoiesis is given in  Figure 3. 
 
 Figure 3. Characterisation of haematopoietic lineages by cluster of differentiation, genetic and 
biochemical markers[28], [32]–[36]. 
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1.2.2 The Stem Cell Niche(s) 
Localised microenvironments that maintain and regulate stem or progenitor cells are 
referred to as a ‘Stem cell niche’[37]. The stem cell niche varies throughout human 
development, for example during embryogenesis; niches reside in the yolk and placenta 
where postnatally HSC niches reside within the bone marrow[38].   
The bone marrow niche is a highly complex microenvironment, where the Extracellular 
Matrix (ECM), growth factors, hormones, adhesion molecules, integrins, cells (i.e. stromal 
cells) and physicochemical cues work in concert to maintain stem cell phenotype as shown 
in the model illustrated in  Figure 4 [39]–[41]. Within the bone marrow, HSCs reside near to 
sinusoids where SCF and other paracrine factors (secreted by MSCs and endothelial cells) 
promote their maintenance [42].  
 
 Figure 4. A model of the stem cell niche, highlighting the complexity of signalling pathways involved in 
HSC maintenance. Diagram taken from [41] 
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1.2.3 Sources of Haematopoietic Stem Cells 
HSCs can be sourced directly from the bone marrow or can be temporarily mobilised into 
the blood stream. Alternative non-invasive sources include umbilical cord blood and 
placenta. Here bone marrow, peripheral blood and umbilical cord blood are reviewed since 
these are the most widely used sources in the clinic.  
1.2.3.1 Bone Marrow 
The bone marrow (BM) is the primary HSC niche in the adult human body where 
approximately 1% of total Mononuclear Cells (MNCs) are CD34+. BM transplants have been 
performed since the 1950’s and consist of painful operations requiring general anaesthesia 
and long hospital stays for both patient and donor. Donor and patient have to be HLA 
matched to reduce the risk of GvHD, meaning those patients with no siblings are at great 
risk of not finding a suitable donor and will have to undergo a non-related BM transplant.  
1.2.3.2 Mobilised Peripheral Blood  
Stem cells can be temporarily mobilised from the bone marrow into the peripheral blood 
with G-CSF injections (sometimes in combination with Plerixafor) [43]. Mobilisation is now 
the preferred choice of stem cell isolation because the process is less painful for the donor 
and does not require administration of general anaesthesia or an operating theatre.  
During the mobilisation process (up to 4 days) stem cells are mobilised into the peripheral 
blood stream and collected using equipment which separates and collects white blood cells 
from the bulk of the blood, whilst filtering out red blood cells and returning them to the 
donor. Higher concentrations of HSCs can be collected from mobilised peripheral blood 
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(MPB) compared with BM - over 1000 CD34+ cells/µL of blood can be achieved with G-CSF 
mobilisation alone [44]. 
1.2.3.3 Umbilical Cord Blood 
Umbilical cord blood (UCB) is one of the preferred non-invasive sources of HSCs available. 
Historically the umbilical cord was disposed of after child birth, however the blood retained 
within the umbilical cord contains HSCs. Often low volumes of UCB mean relatively low 
numbers of HSCs are recovered from the cord which are insufficient to treat the average 
adult [45]. Increased levels of HLA disparity can be tolerated with UCB in comparison to 
other sources of HSCs meaning the availability of HSCs is increased to a wider population 
pool, which is of particular importance to ethnic minorities [46], [47].  
1.3 Considerations and Challenges with Cell Expansion 
HSCs derived from umbilical cord blood offer biological, clinical and ethical advantages over 
other sources. High total nucleated cell count (TNC) is correlated with engraftment success 
and good clinical outcome; with a TNC count of 2x109 cells or 1.2x106 CD34+ cells now 
widely accepted as a minimum threshold for a successful single cord blood transplant [48].  
TNC counts are highly variable between cord blood units due to a number of factors (i.e. 
weight of foetus, size of placenta, processing method used) and low TNC counts are the 
primary reason why the utilisation of banked cord blood units are now estimated at 1-3% 
globally and utilisation rates are declining [49].  
For cord blood banks to be economically sustainable there is now a focus to process only 
those cord blood units meeting the TNC threshold. Although efforts have been made to 
pg. 14 
 
improve processing methods or moving towards automated processing to minimise 
operator variability (such as the Sepax, GE Healthcare).  
Double cord blood transplants have been explored where one unit does not meet the 
minimum TNC threshold, however finding two suitable matches at the same time is 
logistically challenging and economically impractical [50].   
In addition to improving the processing and banking of cord blood units, many research 
groups are exploring ex vivo expansion of HSCs are in order to increase utilisation and 
patient access. Maintaining stem cell or progenitor phenotypes during CD34+ expansion ex 
vivo is challenging, namely due to rapid differentiation and slow engraftment times once 
transplanted.  
Engraftment time can be problematic for HSC transplants particularly where HSCs are 
derived from UCB where CD34+ populations are naive in nature. Slow engraftment leaves 
patients at risk of infection due to the lack of an immune system and infection is one of the 
leading causes for mortality in UCB HSC transplants. Slow engraftment can also be caused by 
stem cell exhaustion following ex vivo expansion as described later. To overcome the issues 
involved in HSC transplants, some studies have looked at administering the patient with two 
fractions of cells; the expanded CD34+ fraction and a proportion of the original cord blood 
fraction which contains higher numbers of mature blood cells which were stored before ex 
vivo manipulation [51].  
Stem cell exhaustion can occur during rapid ex vivo expansion where increases in reactive 
oxygen species (ROS) may lead to poor engraftment when transplanted [52], [53]. Increases 
in ROS arise due to increased metabolic activity upon ex vivo expansion and due to un-
optimised dissolved oxygen in cell culture conditions.  
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A major challenge for cell and gene therapies (particularly T-cell therapies) is the sheer 
number of cells required in the drug product. Currently the consensus in the field is “more is 
better” however; manufacturing large numbers of cells becomes expensive due to the 
volume of media required and scalability of the manufacturing platform.  
Whilst studies have looked at moving towards high density cell cultures and perfusion 
systems to reduce quantities of media required, it leaves the question of whether the 
quality or potency of the cells being administered are suboptimal. Furthermore, defining the 
rarer sub-populations that correlate better with good therapeutic effect is likely to reduce 
the number of cells required for such therapies.  
1.4 Hurdles and Solutions to the Commercialisation of Cell 
and Gene Therapy 
The first gene therapy receiving market authorisation by the EMA was Strimvelis™ (GSK) in 
2016, the gene therapy for ADA-SCID which is priced at ~600K euros per patient. The cost 
has received much criticism from the healthcare industry, however in relation to the life-
long costs of treating an ADA-SCID patient in isolation; it is relatively low in comparison. This 
one dose treatment for a rare disease is unlikely to be a blockbuster medicine due to its high 
costs and low patient numbers.  
If we take this cost for Strimvelis and extrapolate it to clinical indications with much higher 
patient numbers for example in the immuno-oncology field, a price this high is unlikely to be 
reimbursed by public health services or health insurance companies. ChondroCelect™ has 
recently been withdrawn from the market by its manufacturer, TiGenix as of November 
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2016 due to reimbursement issues. Treatment costs can be reduced through the use of 
automation, reducing raw material costs, scaling-up and using Quality by Design (QbD) 
principles.  
1.4.1 Automation 
Automation of cell processing reduces both costs (of raw materials and human resources) 
and reduces product variability by removing operator dependent variation. Automated (fully 
or semi-automated) systems exist for all sections of cell therapy processing, from cell 
washing to fill/finish. Cell washing equipment such as the COBE 2991 (Terumo BCT) have 
been around for many years and widely used in blood banks due to its ease of use and 
robustness. The equipment also uses disposable single-use kits which reduces the risk of 
patient-to-patient carry over and contamination. More sophisticated equipment (CompacT 
selecT, Sartorius and Sepax, GE Healthcare) is capable of handling and culturing of standard 
T-flasks with tractability using barcode readers, with comparability to manual processing 
[54].  
Fully automated systems such as the Prodigy™ (Miltenyi Biotech) is changing the face of cell 
manufacturing processes – the closed-system allows manufacturing outside of cGMP suites; 
greatly reducing costs and processes are available for CAR/TCR manufacturing as well as 
CD34+ manufacturing (see  Figure 5) [55]–[57]. The Prodigy is ultimate evolution of 
manufacturing equipment for autologous therapies due to its scale-out potential. However, 
autologous therapies are likely to manufactured using standard stirred tank bioreactors due 
to their scalability. Furthermore, systems such as the Prodigy are not a one size-fits-all 
solution; it requires significant process development for individual cell therapies and cannot 
yet formulate the drug product with standard formulations involving DMSO.  
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 Figure 5. The fully automated cell therapy processing platform Prodigy by Miltenyi Biotec. Such 
automated systems are key to the realisation and commercialisation of cell and gene therapies.  
1.4.2 Quality by Design 
The Quality by Design (QbD) principle was introduced by the FDA in 2006 to address the 
variation in manufacturing processes of pharmaceuticals and to incorporate the 
International Conference on Harmonization guidelines. QbD integrates scientific knowledge 
and risk analysis into manufacturing process development to address drug manufacturing 
failures caused by manufacturing inefficiencies [58]. The process has been summarised 
in  Figure 6. 
Tools such as Design of Experiments (DoE) can help to elucidate complex interactions 
between manufacturing variables in cell and gene therapies and therefore help to define 
optimal conditions for both target cell numbers and desired cell quality.  Scaled down micro-
bioreactor platforms such as the ambr™ (Sartorius) will allow such DoE experiments to be 
performed. 
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The use of QbD principles for the manufacture of cell and gene therapies are likely to 
accelerate development, decrease process variability, reduce cost of goods and assist with 
regulatory compliance [58].   
 
 Figure 6. An overview of Quality by Design process to aid cell therapy manufacturing. Adopting QbD 
principles in cell therapy manufacturing processes will accelerate development.  
 
1.4.3 Safety and Efficacy  
Despite the potential of cell and gene therapies, the inherent complexity of such treatments 
gives rise to greater safety concerns when we compare them to conventional 
pharmaceuticals and biopharmaceuticals.  
Define desired product quality 
charactersitsics (QTPP) 
Risk assesment to define CQA to 
meet QTPP  
Identify attributes that influence 
saftey and efficacy of the product 
(CPP) 
Design space that quantifies how 
parameter variability affetcs  quality 
attributes (i.e. DOE). 
Develop control strategy to maintain 
process parameters within a range 
that ensures product quality. 
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Purity of the cell therapy drug product is an important consideration. Contamination of non-
target cell types poses safety and potency risks of the final drug product. Contaminating cell 
types, for example in HSC and T-cell therapies, can affect the potency of the therapy by 
competitively repopulating the blood system [59]. Furthermore, cell impurities may suggest 
inefficient manufacturing processes which may lead to variable clinical outcomes. Other 
impurities can stem from microorganisms that contaminate the culture. Microorganism 
contaminants can arise from the donor, during ex vivo manipulation and from raw material 
sources such as serum and animal derived supplements such as growth factors. Due 
diligence can be taken by moving towards serum free manufacturing process and or 
recombinant proteins produced in non-mammalian cell types – such steps also reduce 
batch-to-batch manufacturing variability. Release testing should extensively screen for 
microorganism contamination which adds to the cost of cell therapies and increases the 
time to administration.  
Graft versus host disease for allogeneic treatments remains a significant risk for patients 
where suitable matches are not available. This is particularly an issue for patients from 
ethnic minorities where rare HLA types mean donors are not readily available.  
Tumorigenicity of cell and gene therapy is a major concern for the industry and the long 
term effects of therapies with market approval are still widely unknown. Tumourgeneticity 
can arise from the method of genetic modification of cells, where insertion of genes via viral 
vectors can cause mutations causing uncontrolled growth of progeny cells. As little as 0.025% 
of undifferentiated pluripotent cells can lead to teratoma formation [60]. Studies have also 
shown that injection of autologous stem cells into kidneys have developed into tumours; 
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highlighting the need for the field to better understand the effects of administration sites on 
tumour formation [61].  
Due to the risks associated with cell and gene therapies and unknown long-term effects, 
regulatory authorities require extensive pre-clinical and clinical safety data and analytical 
testing methods for IND applications. Such extensive data not only increases development 
time lines, but also adds to development costs. Albeit, the FDA is committed to less rigorous 
safety testing by working with developers throughout the life-cycle of a product. The FDA 
have introduced programmes such as ‘breakthrough therapy designation’ and ‘accelerated 
approval’ expedite therapy approvals[62].  
1.5 Growth Factors 
Growth factors were first discovered during the 1950-1960s by Cohen and Levi-Montalcini 
during their research into the growth of nerves. Their research led to the discovery of Nerve 
Growth Factor (NGF) and Epidermal Growth Factor (EGF) for which they won a Nobel Prize 
in 1986[63]–[65]. Growth factors are defined as proteins that are secreted by cells that 
regulate a wide range of biological effects including cell proliferation, migration, 
differentiation, morphogenesis and angiogenesis. The terms cytokine and growth factor are 
often interchanged however, cytokines are proteins which are secreted by immune cells 
that induce inflammatory responses. The first cytokine, interferon, was discovered by Isaacs 
and Lindenmann in 1957[66]. 
Defined growth factor ‘cocktails’ are supplemented to cell culture media in order to support 
the growth and differentiation of cells in vitro. The first successful attempts of cell culture 
was achieved by Harrison in 1907 who realised the nutritional and growth support that 
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clotted lymph provided to explanted tissues[67], [68]. Building on from this work, it was 
quickly realised that plasma or serum was essential for the growth and nutritional support 
of cells[69]–[71]. However, it wasn’t until 1980 that growth factors were found to be the 
component in plasma or serum which provided growth and support of cells; furthermore, 
the requirements of growth factors were found to be different for every cell type[72].  
1.5.1 Immobilised Growth Factors 
In vivo, growth factors can exist in both soluble and matrix bound forms. Matrix bound 
growth factors associate with glycosaminoglycan’s (heparin or heparan sulfate) or proteins 
of the extracellular matrix (ECM) including fibronectin and collagen[73], [74], some growth 
factors such as SCF and Flt-3L have distinctly separate soluble and membrane bound forms 
in vivo[75], [76].  
The ECM provides a storage mechanism for growth factors as they are protected from 
degradation by proteolytic enzymes, receptor-mediated endocytosis and other 
physicochemical cues for which soluble growth factors are susceptible to degradation. 
Soluble growth factors consequently have very short half-lives with bFGF having a half-life of 
just three minutes in vivo[74], [77].  Rapid release of matrix associated growth factors can 
be achieved by proteolytic activation (a growth factor which is in its latent state when 
immobilised but becomes biologically active when released in a soluble form), leading to a 
localised concentrated growth factor microenvironment in response to tissue injury for 
example. Without proteolytic activation, a response to tissue injury would be a timely 
process as growth factors would need to be produced through gene expression and 
transcription.    
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Matrix bound proteins often retain their biological potency however some exist in a latent 
state (e.g. TGF-β, HGF and CSF-1)[78]–[80]. The literature also suggests that some matrix 
bound growth factors (i.e. VEGF) have demonstrated an increased biological potency as 
compared to soluble counterparts[81]; additionally a prolonged response can also be 
achieved in comparison to their soluble counterparts[82]–[84]. Increased potency can be 
achieved by ligand multivalency and receptor clustering which has been shown to produce 
distinct signalling pathways from their soluble counterparts[85].  
Numerous recent studies have shown the importance of growth factors (SCF) and notch-
ligands for the expansion of UCB derived HSCs [86], [87].  
1.6 Applications of Magnetic Microparticles in Cell and Gene 
Therapy 
Micro-Particles are an ideal surface for the immobilised growth factors since they offer a 
large surface area to volume ratio, meaning high localised concentrations can be achieved, 
but also so they can be used in scalable manufacturing systems such as stirred tank 
bioreactors. The magnetic element of the particles will also allow manipulation of the 
growth factors independently of the media bulk.  
Magnetic particles in biomedical research are becoming increasingly popular since they are 
versatile and biocompatible materials which have many potential applications.  
Magnetic microparticles typically range from 0.1-100µm in diameter which consist of a 
polymer core (usually polystyrene) and coated with a magnetic material such as magnetite 
or maghemite (both are iron oxides which have ferrimagnetic properties). Iron coatings 
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result in the particles having low levels of agglomeration and are highly biocompatible 
because Fe2+ ions are endogenous inside of the human body where metabolic pathways 
exist for the adsorption, distribution, metabolism and excretion of the metal[88].  
Magnetic microparticles have paramagnetic properties meaning that electrons within the 
iron atoms are able to align with the magnetic field - they hold no residual magnetism but 
when placed in a magnetic field they exhibit magnetic properties.  
Magnetic particles have received regulatory approval for some biomedical applications such 
as, MRI contrast reagents (i.e. Ferucarbotran and Ferumoxtran-10) and cell isolation 
(CliniMACS™, Miltenyi Biotec). More applications of magnetic particles can be seen in  Figure 
7. 
Activation of T-cells is induced by the formation of T-cell receptor complexes[89]. In vivo, 
the complexes often involve the presentation of anti-CD3 and anti-CD28 by dendritic cells 
leading to a cascade of events leading to T-cell activation and proliferation. Dynabeads™ 
(Life Technologies) are the leading technology for ex vivo T-cell expansion, where CD3 and 
CD28 antibodies are conjugated onto Protein A functionalised magnetic particles – 
recapitulating the presentation by dendritic cells in vivo. Dynabeads™ have been widely 
used over many years for the activation of T-cells in an ever increasing number of oncology 
clinical trials[90]. Similar technologies include the capture of proteins in a ‘quickgel’ on the 
surface of magnetic microparticles (MagCloudz™, Quad Technologies).  
The safety, biocompatibility and current usage of magnetic particles in numerous 
biomedical fields means magnetic microparticles are an attractive substrate for growth 
factor immobilisation.  
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 Figure 7. Magnetic particles are widely used in for biomedical applications due to their biocompatibility 
and low immunogenicity.  
  
pg. 25 
 
1.7 Thesis Objectives 
The objective of this project was to develop a scalable growth factor immobilisation 
technique in order to address some of the raw material cost issues surrounding the 
manufacturing of cell and gene therapies and to demonstrate some of the functional and 
process benefits of using immobilised growth factors as opposed to standard soluble growth 
factors. This thesis aims to: 
• Develop a novel growth factor immobilisation technology using magnetic 
microparticles to allow scalability in standard stirred tank bioreactor platforms.  
• Develop functional assays to assess and optimise the activity of immobilised growth 
factors in comparison to soluble equivalents.  
• Demonstrate the unique functional activities of immobilised growth factors in 
comparison to soluble equivalents. 
• Demonstrate the scalability and process benefits of immobilisation using magnetic 
particles. 
• Finally, demonstrate the immobilisation technology in a model (clinically relevant) 
system for the expansion of umbilical cord blood derived haematopoietic stem cells.  
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2 Materials and Methods 
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Methods 
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2.1 Cell Culture 
The following protocols were used to culture cell lines and primary cells unless stated 
otherwise.  
2.1.1 TF-1 Human Erythroleukemia Cell Line 
TF-1 cells are dependent on GM-CSF and therefore chosen to investigate and compare the 
activity of soluble and immobilised GM-CSF. TF-1 cells were obtained frozen from ATTC 
(ATTC, UK) and cultured according to manufacturer’s recommendations. A description of 
media formulations are presented in  Table 2.  
TF-1 cells were maintained in culture at a density of 2×105 to 8×105 cells/mL with complete 
media in a humidified incubator (5% CO2, 37ºC). Complete media was replenished every two 
to three days. 
A description of cryopreservation and thawing of TF-1 cells are described in section  2.1.1.1. 
 TF-1 Media formulations Table 2.
Media Type Description 
Complete Media RPMI 1640 (Phenol Red Free, Glutamine Free; ThermoFisher Scientific) 
10% v/v Heat Inactivated Foetal Bovine Serum (Life Technologies) 
5mM (final concentration) Glutamax (ThermoFisher Scientific) 
5 ng/mL carrier free GM-CSF (R&D Systems)  
Assay Media As Complete Media without GM-CSF 
Freezing Media As Complete Media with 10% DMSO 
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2.1.1.1 TF-1 Cryopreservation and Thawing 
Cryopreservation 
Cells were concentrated to 1x106 cells/mL in cold freeze media and 0.5 mL was transferred 
to a 1.5 mL cryo-vial. The cryo-vials were placed in a Mr Frosty (controlled rate freezer) at -
80ºC for 24 hours before transferring to the vapour phase of liquid nitrogen for long term 
storage.  
Thawing 
A vial of cells were removed from storage in the vapour phase of liquid nitrogen and 
transferred to a water bath at 37ºC. The vial was removed from the water bath when a 
miniscule ice crystal was all that remained in the vial and was sprayed with 70% IMS before 
placing into a Biological Safety Cabinet (BSC). The cells were removed from the vial using a 
sterile Pasteur pipette and transferred into 5mL of pre-warmed complete medium, washing 
the inside of the vial to remove all cells. Cells were centrifuged (300g, 5 minutes) and the 
supernatant was aspirated to remove DMSO. Cells were then re-suspended in a volume of 
complete medium to achieve 2x105 cells/mL and transferred to a T25 Culture Flask (Fisher 
Scientific) and placed in a humidified incubator (5% CO2, 37ºC).   
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2.1.2 M-07e Cell Line 
M-07e cells are dependent on GM-CSF, SCF and TPO, therefore chosen to investigate and 
compare the activity of multiple soluble and immobilised growth factors. Frozen M-07e cells 
were obtained from Creative Bioarray and cultured according to manufacturer’s 
recommendations. A description of media formulations are presented in  Table 3. 
 M-07e media formulations. Table 3.
Media Type Description 
Complete Media RPMI 1640 (Phenol Red Free, Glutamine Free; ThermoFisher Scientific) 
10% v/v Heat Inactivated Foetal Bovine Serum (Life Technologies) 
5mM (final concentration) Glutamax (ThermoFisher Scientific) 
5 ng/mL carrier free GM-CSF (R&D Systems)  
10 ng/mL carrier free SCF (R&D Systems) 
Assay Media As Complete Media without GM-CSF and SCF 
Freezing Media As Complete Media with 10% DMSO 
 
M-07e cells (Creative Biosystems, USA) were maintained in culture at a density of 4×105 to 
1×106 cells/mL with complete media in a humidified incubator (5% CO2, 37ºC). Media was 
replenished every two to three days. 
A description of cryopreservation and thawing of TF-1 cells are described in section  2.1.1.1. 
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2.1.3 Umbilical Cord Blood Derived CD34+ Cells 
Umbilical cord blood not suitable for clinical transplant was received from Anthony Nolan 
(Nottingham, UK). Blood was processed fresh, or incubated on a tube rotator overnight at 
3ºC before processing.  
Mononuclear cells (MNCs) were isolated by density gradient separation with Ficoll Paque. 
CD34+ cells were isolated from the MNCs fraction by magnetic separation using a CD34 
microbead kit, LS columns and quadroMACS magnet (Miltenyi Biotec) as per the 
manufacturers protocol.   
Cells were cultured in complete media. Cells were seeded at 5x105/mL and were reset back 
to initial seeding density every 3 days through centrifugation and re-suspension of cells in a 
1:1 replacement of spent medium:fresh medium, cytokines were added at double 
concentration in fresh medium to replace degraded cytokines in the spent fraction.  
A description of media formulations are listed in  Table 4. 
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 CD34+ Media Formulations. Table 4.
Media Type Description 
Complete Media Iscove’s Modified Dulbecco’s Medium (IMDM with Glutamax, 
Invitrogen) 
20% v/v BIT 9500 Serum Substitute (Stem Cell Technologies) 
100 ng/mL SCF, IL-3 and Flt-3L (R&D Systems) 
50 ng/mL TPO (R&D Systems) 
Assay Media As Complete Media without growth factors 
Freezing Media 80 % IMDM (with Glutamax, Invitrogen) 
10 % Heat Inactivated Foetal Bovine Serum (Life Technologies) 
10% DMSO 
 
2.1.3.1 CD34+ Cryopreservation and Thawing 
Cryopreservation 
Cells were concentrated to 1x106 cells/mL in chilled freeze media and 0.5 mL was 
transferred to a 1.5 mL cryo-vial. The cryo-vials were placed in a Mr Frosty (controlled rate 
freezer) at -80ºC for 24 hours before transferring to the vapour phase of liquid nitrogen for 
long term storage.  
Thawing 
A vial of CD34+ cells were removed from storage in the vapour phase of liquid nitrogen and 
transferred to a water bath at 37ºC. The vial was removed from the water bath when a 
miniscule ice crystal remained in the vial and was sprayed with 70% IMS before placing into 
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a Biological Safety Cabinet (BSC). The cells were removed from the vial using a sterile 
Pasteur pipette and transferred into 5mL of pre-warmed complete medium, washing the 
inside of the vial to remove all cells. Cells were centrifuged (300g, 5 minutes) and the 
supernatant was aspirated to remove DMSO. Cells were then re-suspended in a volume of 
complete medium to achieve 5x105 cells/mL and transferred to a T25 Culture Flask (Fisher 
Scientific) and placed in a humidified incubator (5% CO2, 37ºC).   
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2.2 Cell Counting  
The ViCell counting method was used for ambr™ experiments, whereas the NC-3000 was 
used for static culture experiments unless otherwise stated. 
2.2.1 ViCell (Trypan Blue Exclusion) 
For AMBR experiments, 500µl of cell suspension (concentrated or diluted with medium) was 
taken for analysis, and placed into the sampling cup of the automated cell counter. Counts 
were an average of 50 images per sample.  Counting settings were: 
• Minimum Diameter (µm): 6 
• Maximum Diameter (µm): 20 
• Number of images: 50 
• Trypan blue mixing cycles: 3 
• Cell brightness (%): 85 
• Cell Sharpness: 100 
• Viable cell spot brightness (%): 65 
• Viable cell spot area (%): 10 
• Minimum circularity: 0.8 
• Decluster degree: None 
2.2.2 NC-3000 
A 100 µL cell suspension sample was taken and dispensed into a 1.5 mL eppendorf tube.  
Approximately 60 µl of cell suspension was aspirated using a Via-1 cassette. The cassette 
was immediately placed into the NC-3000 and the automated mammalian cell count and 
viability protocol was selected and run. Acridine Orange and DAPI dyes are used to 
determine cell viability.  
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2.2.3 Flow cytometry 
Typically 50 µL of cell suspension were sampled by the AMBR and dispensed into a 96 well 
plate containing 50 µL of 4% paraformaldehyde (PFA). Spare wells and in between wells 
were filled with sterile water and the plate was lidded to prevent evaporation of samples. A 
plate was often left for 10 hours at room temperature depending on the frequency of 
sampling. Plates were analysed by mixing wells with a multichannel pipette prior to analysis 
on a flow cytometer. A fixed volume of 50 µL was analysed with a fixed medium flow rate 
for all wells. To calculate an event count, cell populations were gated to remove debris in 
flow cytometry analysis software (FlowJo). 
2.3 Agitated Cell Culture 
A micro-scale stirred tank bioreactor platform (ambr®; Sartorius Stedim, UK.) was used to 
determine the scalability of the immobilization method. Unless otherwise stated, 
physicochemical parameters were set to: 100% DO2 (oxygen delivery), pH 7.4, temperature 
37°C, stir speed 350 rpm. Sparged vessels were used with 1% antifoam additions (Antifoam 
C, Sigma Aldrich, UK) performed every 24 h beginning at 0 h. The ambr® was programed to 
sample from vessels as required, dispensing into a microtiter plate containing 4% 
paraformaldehyde (Sigma Aldrich, UK) which was then analysed on a flow cytometer to 
determine cell and particle number. A complete media change was performed every 48–72 
h and cells were reset to a density of 2 × 105 cells/mL. For iGF conditions, particles were 
retained within the vessel by holding a magnet against the vessel, whilst performing media 
changes. 
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For particle removal; The AMBR 1mL pipette tips were modified to accommodate magnets 
(first 4 magnets; neodymium 0.58kg pull 4mmx4mm) and autoclaved. AMBR vessel caps 
were removed and a sterile magnetic pipette tip was manually inserted into vessels for 5 
minutes with continuous stirring.    
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2.4 Functional Assays 
Growth factor dependent cell lines were used to assess the functional activity of 
immobilised and soluble growth factors.  
2.4.1 TF-1 Functional Assay 
TF-1 cells were used to assess the function of GM-CSF. Unless otherwise stated, TF-1 cells 
were washed three times in GM-CSF free media and starved of GM-CSF for 24 hours. Either 
soluble GM-CSF (sGM-CSF) or immobilized GM-CSF (iGM-CSF) was supplemented to starved 
TF-1 cells and a growth rate was determined thereafter using flow cytometry. 
2.4.2 M-07e Functional Assay 
M-07e cells were used to assess the function of GM-CSF, SCF, Flt-3L and TPO. Unless 
otherwise stated, M-07e cells were washed three times in GF free media and starved of GF 
for 24 h. Either soluble GF (sGF) or immobilized GF (iGF) was supplemented to starved M-
07e cells and a growth rate was determined thereafter using flow cytometry. 
2.4.3 CD34+ Functional Assay 
CD34+ cells were used to assess the function of SCF. Unless otherwise stated, CD34+ cells 
were washed three times in GF free media and starved of GF for 24 h. Either soluble GF (sGF) 
or immobilized GF (iGF) was supplemented to starved CD34+ cells and a growth rate was 
determined thereafter using flow cytometry. 
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2.4.4 Dose-response Assay (AlamarBlue®) 
The AlamarBlue® assay was optimised as per  Appendix A – Optimisation of AlamarBlue 
Assay. In brief, cells were cultured for 48 hours in a 96 well plate, where 10% (v/v) 
AlamarBlue was dispensed into each well and incubated for 3.5 hours in a humidified 
incubator (37ºC, 5% CO2). Afterwards, the plate was removed from the incubator and 
allowed to cool to room temperature (protecting from direct light) for 0.5 hours before 
measuring the fluorescence on a plate reader.  
The effective concentration 50 (EC50) was calculated in GraphPad Prism software using a 
four-parameter variable slope curve.  
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2.5 Growth Factor Immobilisation 
The following protocols were used for four different protein immobilisation methods unless 
otherwise stated.  
2.5.1 Streptavidin Method 
The immobilization method involves a two-step reaction (summarised in  Figure 8): 
Step 1 – Growth factor biotinylation 
1) Lyophilized carrier free GFs (R&D Systems, UK) were re-suspended in PBS at a 
concentration of 50 μg/mL. 
2) NHS-PEG2000-biotin (Nanocs Inc., USA) was suspended in anhydrous DMSO at the 
required molar concentration for the individual experiment being carried out and 
used immediately. 
3) Equal volumes of GF and NHS-PEG2000-biotin were mixed in LoBind Protein 
Eppendorf tubes and vortexed for 2 h at room temperature. 
Step 2 - Immobilization of biotinylated growth factors 
4) 2.8 μm streptavidin coated magnetic particles (Solulink, USA) were placed on a 
magnetic stand (MagnaRack™ Magnetic Separation Rack, ThermoFisher Scientific) 
and the supernatant removed. 
5) Biotinylated GF solution from step 1.3 was added to the prepared particles and 
vortexed overnight at 4–8 ºC. 
6) iGFs were washed three times in 500 μL of PBS using a magnetic stand and used 
immediately. 
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 Figure 8. Growth factor immobilisation reaction using the ‘Streptavidin Method’. The immobilisation 
method consists of a two-step reaction, where first the GF is biotinylated and secondly immobilised 
onto streptavidin functionalised magnetic microparticles.  
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2.5.2 Carboxyl Method 
Primary amines of GM-CSF were modified to thiol functional groups using TCEP reagent as 
per the manufacturer’s instructions. The modified GM-CSF (R&D Systems) was then 
pegylated using a heterobifunctional PEG molecule, NH2-PEG2000-Maleimide (Nanocs Inc., 
USA). The PEG molecule was re-suspended at 10 mg/mL. Three 50 µL aliquots of the PEG 
were mixed with three separate 50µL aliquots of GM-CSF of different concentrations (10 
µg/mL, 2.5 µg/mL and 0.3 µg/mL) at room temperature for two hours using a tube rotator.  
The pegylated GM-CSF suspension was supplemented to dry pre-functionalised 2.0-2.9um 
carboxyl magnetic particles (Spherotech Inc., USA);  1x106 particles per 100µl of PEGylated  
GM-CSF. EDC reagent was then supplemented at a final concentration of 1mM. The 
suspension was mixed overnight at 3-4ºC using a tube rotator. 
The particles were washed three times using nuclease free water, centrifuging briefly at 
10,000rpm and placing on a magnetic stand whilst removing the supernatant. The final 
immobilised GM-CSF particles were re-suspended in assay media. 
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2.5.3 Fibronectin Method 
Lyophilised human fibronectin (R&D Systems) was suspended in PBS at a final concentration 
of 10 mg/mL. 50µL of fibronectin was supplemented to dry plain (non-functionalised) 
magnetic particles (Spherotech Inc., USA) and mixed at room temperature on a tube rotator 
for 2 hours. Fibronectin coated particles were washed three times with nuclease free water, 
centrifuging briefly at 10,000rpm and placing on a magnetic stand whilst removing the 
supernatant.  
1x106 particles per 100µl of PEGylated GM-CSF Dry fibronectin coated particles were re-
suspended in three 50µL aliquots of GM-CSF of different concentrations (10 µg/mL, 2.5 
µg/mL and 0.3 µg/mL) at 3-8ºC overnight using a tube rotator. The particles were then 
washed three times using nuclease free water, centrifuging briefly at 10,000rpm and placing 
on a magnetic stand whilst removing the supernatant. The final immobilised GM-CSF 
particles were re-suspended in assay media. 
2.5.4 Solulink Method 
Immobilisation of GM-CSF was achieved using the MagnaLink BeadLink Kit (Solulink Inc, 
USA). The manufacturer’s immobilisation protocol was followed except for the following: 
All of the reagents were split into thirds and the yellow and red spin columns were re-used 
three times for each of the GM-CSF concentrations (10 µg, 2.5 µg, and 0.63 µg/mL). The spin 
columns were washed once with nuclease free water before re-use.  
The final immobilised GM-CSF particles were re-suspended in nuclease free water at 3-8ºC 
until use. 
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2.6 Nutrient and Metabolite Analysis 
Media supernatants (1mL) were sampled and stored in 1.5 mL eppendorf tubes at -80ºC 
until time of analysis. Samples were thawed at room temperature and vortexed briefly 
before analysis on the BioProfile Flex (Nova Biomedical). QC tests and calibrations were 
performed as per the manufacturer’s recommendations.  
2.7 Protein Quantification 
Flow cytometry based methods were used to quantify immobilised growth factors and ELISA 
based methods were used to quantify soluble growth factors. 
2.7.1 Immobilised Growth Factor Concentration 
Surface Concentration 
2 × 105 iGF particles were incubated in 50 μL of flow cytometry stain buffer containing the 
required concentration of conjugated monoclonal antibodies (R&D Systems, UK) for 1 h at 
room temperature. Where conjugated antibodies were unavailable, antibodies were custom 
conjugated using an APC-Antibody conjugation kit (Solulink, USA). In parallel, iGF particles 
were also stained with an antibody isotype control. iGF particles were then washed once 
with PBS and re-suspended in 100–500 μL of PBS. Fluorescence intensity was measured 
using FACS Canto II flow cytometer (BD Biosciences, UK) by taking a minimum of 10,000 
events at medium flow rate. Flow cytometry data was analysed using FlowJo software, 
where a singlet population was discriminated. Fluorescence reference standards (Quantum 
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MESF; Bangs Labs Inc., USA) were run on the same day to determine the mean mass of iGF 
per particle using the net geometric of the singlet population.  
Total Concentration 
Final particle concentration was determined using flow cytometry where a fixed volume of 
sample was analysed using medium flow rate. Flow cytometry data was analysed using 
FlowJo software (Treestar, USA) and cells/mL was generated from the particle population 
gate. The particle count per mL was then multiplied by the mean surface concentration of 
iGF.  
2.7.2 Soluble Growth Factor Concentration 
Soluble GF concentrations were determined with a Bio-Plex Magpix Multiplex Reader (Bio-
Rad Laboratories, UK) using pre-mixed Human Magnetic Luminex assay kits with SCF and 
GM-CSF analytes (R&D Systems, UK) as per the manufacturer’s instructions. Samples were 
prepared by sampling cell suspensions and removing cells (by centrifugation), and storing 
the supernatant in 1.5 mL protein LoBind eppendorf tubes at -20°C until use. 
2.8 Immunophenotyping 
Approximately 1x105 cells were stained with the appropriate CD antibody in a total volume 
of 100µL per well at room temperature for 30 minutes. Cells were pelleted by centrifugation 
and re-suspended in 100µL of PBS to remove non-bound antibody. IgG isotype controls 
were used in parallel to assist in gating of the positive cell population. Stained cells were 
analysed on the FACS Canto II HT. Antibodies were titrated before analysis.   
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2.9 Magnetic removal 
A variety of methods were used to remove and retain magnetic particles in culture. The 
methods used are listed below. 
2.9.1 Magnetic pipette tips 
 
 Figure 9. Custom made magnetic pipette tip. A 1 mL pipette tip was trimmed and four small magnets 
were placed inside of the tip and autoclaved to ensure sterility.  
2.9.2 Magnetic rack 
 
 Figure 10. A magnetic stand to accommodate multiple 1.5 mL eppendorf tubes.  
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2.9.3 Magnetic plate 
 
 
 Figure 11.  A) A magnetic plate for 96 well plates B) capture of magnetic particles during a media change 
in an AMBR vessel.                                                          
2.10 Equations 
Equation 1. Cell Population Doublings (PD). 
𝑃𝑃𝑃𝑃 = log 10 �𝐹𝐹𝐹𝐹𝑆𝑆𝑃𝑃�log 2  
Where PD = population doublings; FN= final cell concentration (cells/mL); SD = starting cell 
concentration (cells/mL). 
2.11 Statistical Analysis 
To determine the statistical significance of one variable between two groups, a student’s 
two-tailed T-Test was performed. To determine the statistical significance of one variable 
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between three or more groups a one-way ANOVA was performed followed by Dunnett’s 
test for multiple comparisons. To determine the statistical significance of two variables 
between three or more groups a two-way ANOVA was performed followed by Sidak’s test 
for multiple comparisons. 
For all tests a P ≤ 0.05 was deemed significant. All statistical tests were performed using 
GraphPad Prism 6 (GraphPad Software Inc., USA). 
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Materials 
 List of reagents Table 5.
Description Supplier Cat/Model Number 
Anti-Human CD133-APC R&D Systems FAB11331A-025 
Anti-Human CD34-FITC BD Biosciences 555821 
Antifoam A Sigma-Aldrich A6582-100G 
Carboxylated Functionalised Particles Spherotech CM-20-10 
CD34 Microbead Kit, Human Miltenyi Biotec 130-046-702  
Distilled Water Life Technologies 10977-035 
DMSO Sigma Aldrich 471267-1L 
EDC Thermo Scientific  22980 
Ficoll-Paque GE Healthcare 17-1440-02 
FLT-3L R&D Systems 308-FK-025/CF 
Glutamax Life Technologies 35050-038 
Heat Inactivated FBS (US Origin) Life Technologies 10082-147 
Human recombinant EPO R&D Systems 307-ER-050/CF 
Human recombinant GM-CSF R&D Systems 215-GM-050/CF 
Human recombinant SCF R&D Systems 255-SC-200/CF 
Human recombinant TPO R&D Systems 288-TP-200/CF 
IMDM BioChrom F 0465 
L-glutamine Fisher Scientific 11500626 
LS separation columns Miltenyi Biotec 130-042-401  
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MagnaLink BeadLink Kit Solulink A-9404-002 
MagnaLinkBeadLink Kit Solulink A-9404-002 
MagnaRack™ Magnetic Separation Rack ThermoFisher CS15000 
Mal-PEG-NHS Nanocs Inc PG2-MLNS-2k 
NC-3000 Via-1 Cassettes  Sartorius 16704-000070 
NH2-PEG(2000)-Mal Nanocs Inc. PG2-AMML-2k 
NHS-PEG(10000)-Biotin Nanocs Inc.  PG2-BNNS-10k  
NHS-PEG(2000)-Biotin Nanocs Inc. PG2-BNNS-2k 
NHS-PEG-Biotin Nanocs Inc PG2-BNNS-2k 
PE Rat Anti-Human GM-CSF BD Biosciences 554507 
PE Rat IgG2a K  Isotope Control BD Biosciences 554689 
PFA Sigma Aldrich F8775-25ML 
Phosphate Buffered Saline SLS BE17-516F 
Plain Magnetic microparticles Spherotech PM-20-10 
Quantum MESF R-PE Bangs Laboratories 899 
RPMI 1640 Life Technologies 32404-014 
Serum Substitute (BIT 9500) Stem Cell Technologies 09500 
Streptavidin Functionalised Particles Solulink M-1003-020 
TCEP Thermo Scientific 20490 
TF-1 Human Erythroleukaemia Public Health England 93022307 
TRIS Buffer Life Technologies AM9855G 
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 List of consumables Table 6.
Description Supplier Cat/Model Number 
24 Deep Well Plate Tap Biosystems A-0038 
Costar 48 Well Plate SLS 3548 
96 well black walled plate BD Falcon 353219 
96 Well Plate SLS 3799 
AMBR 15 Vessels (Sparged) TAP Biosystems 001-0B80 
Protein LoBind Eppendorfs (1.5mL) Fisher Scientific 10708704 
T25 Culture Flask Fisher Scientific TKT-130-170F 
T75 Culture Flask Fisher Scientific TKT-130-210T 
 
 List of instruments and equipment Table 7.
Description Supplier Cat/Model Number 
AMBR 15 TAP Biosystems (Sartorius) N/A 
Biological Safety Cabinet Herasafe KS Class II N/A 
Bioprofile FLEX  Nova Biomedical N/A 
Centrifuge Sigma 3-16 pk 
Countess Automated Cell Counter Life Technologies C10227 
FACS Canto II HT Flow Cytometer BD Biosciences 338962 
FLUOstar Omega Plate Reader BMG Labtech N/A 
Guava Easycyte 8HT Flow Cytometer Merck Millipore 0500-4005 
Incubator Thermo Scientific Heraeus HERA Cell 150 
Magnetic Rack Life Technologies CS15000 
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Magnets for pipette tip modification 
(neodymium 0.58kg pull 4mmx4mm) 
First4magnets F340SH-25 
Micro-centrifuge Sigma 1-14 
Microscope Nikon N/A 
NucleoCounter NC-3000 Chemometec 16704-000060 
QuadroMACS magnetic separation column Miltenyi Biotec 130-090-976  
ViCell Automated Cell Counter Beckman Coulter Vi-Cell XR 
Water Bath Grant Sub Aqua 26 Plus 
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3 The Development of a Growth Factor Immobilisation 
Technology for use in Cell Culture Systems 
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3.1 Introduction 
The costs of cell therapies have been identified as a major hurdle commercialisation and 
patient access[91]. Costs can be attributed largely to the quantities of cell culture media and 
supplements such as growth factors which are required in high concentrations (e.g. SCF is 
usually supplemented at concentrations ≥100 ng/mL).  
Steps have been taken to move towards perfusion systems which maintain levels of 
nutrients and supplements whilst minimising metabolic by-products and inhibitory 
paracrine signals [92], [93]. However, perfusion systems are limited by a lack of on-line 
feedback sensors and mechanisms, meaning there is often a delay between manual 
measurement, analysis of results and adjusting feeding regimes to compensate for cell 
number and or metabolic activity [45], [94]. Furthermore, cell expansion protocols for HSCs 
and T-cells can typically be 7-14 days meaning media requirements can remain a significant 
cost even in perfusion systems [45], [94]–[98]. Consequently, reducing total quantities or 
improving the performance of media or supplements (primarily expensive growth factors) 
would represent a significant advancement for the reduction in cost of goods for cell and 
gene therapies.  
The extracellular matrix plays an important role is presenting a variety of factors in an 
immobilised form, including adhesion molecules, integrins and growth factors. Maintenance 
of stem cell phenotype or differentiation into more specialised cell types is regulated by a 
number of physicochemical factors in the stem cell niche working in concert in a 
spatiotemporal fashion[99].  The niche comprises of short-term cyclical and injury mediated 
regenerative responses and is far from a static environment [100].  
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The following chapter discusses the development of a novel growth factor immobilisation 
method using magnetic microparticles as an immobilisation substrate. Immobilisation 
methods were designed by evaluating and building upon current available methods.  
A selection of methods was assessed using a functional assay utilising a growth factor 
dependent cell line. The quantity of immobilised growth factor was determined using a 
custom developed flow cytometry assay that allowed a direct comparison between 
functional effects and immobilised concentrations. 
3.1.1 Protein Immobilisation Methods 
 
Immobilisation of growth factors for the purpose of cell culture can be achieved via a wide 
range of methods comprehensively described elsewhere [101]. Methods were shortlisted 
and screened on the basis of meeting the following criteria: 
• A widely used and accepted technique (or derivative thereof), 
• Clinically compatible reagents and materials, 
• Mild chemical reactions to prevent protein degradation and ‘click’ chemistry (no 
extensive modification of functional groups), 
• Inexpensive and rapid process with a low number of process steps, 
• And (or) a commercially available protein immobilisation kit.  
 Table 5 summarises a selection of immobilisation techniques along with their advantages 
and limitations. 
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 A comparison of commercially available and customised protein immobilisation methods. Table 8.
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3.1.1.1 Shortlisted immobilisation methods for initial screening experiment 
In an initial screening experiment a selection of immobilisation techniques were 
investigated to compare their functional performance in a growth factor dependent cell line. 
The following four conjugation methods were shortlisted by meeting the critea listed in 
section  3.1.1.  
3.1.1.1.1 Carboxyl 
One of the most common ways of immobilising proteins is to use a reducing agent (TCEP) to 
modify disulphide bonds to thiol groups which spontaneously react with maleimide groups. 
Incorporating a PEG linker molecule between the protein and surface allows the steric 
presentation of proteins to be controlled by altering the PEG linker length. A forward and 
reverse version of the reaction can be performed by PEGylating either the particle or 
protein first as shown in  Figure 12. 
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 Figure 12. Carboxyl immobilisation technique chemical reaction. (Left) Forward Reaction - Disulphide 
bonds within the GM-CSF molecule are transformed to thiol functional groups that spontaneously 
react with the Maleimide functional group of the heterobifunctional PEG compound, resulting in 
the loss of hydroxide ions. Secondly, the pre-functionalised carboxylated magnetic particles are 
activated with a carbodiimide reagent (EDC) resulting in a dehydration reaction (loss of water). The 
activated carboxylic acid groups undergo nucleophilic attack from the primary amine group of the 
PEG compound where the growth factor is immobilised and water is released as a by-product. 
(Right) Reverse Reaction – The reverse reaction involves similar chemical reactions to the forward 
reaction however, the carboxyl particle is first conjugated to the PEG linker molecule and finally the 
PEGylated particle is conjugated to the GM-CSF molecule. 
 
3.1.1.1.2 Streptavidin 
The streptavidin-biotin method is one of the most widely used conjugation methods in 
biotechnology due to its bond strength (strongest non-covalent bond), simplicity of the 
reaction and specificity. Incorporation of a PEG molecule allows the steric presentation of 
the growth factor to be tuned by altering the PEG molecular weight as illustrated in  Figure 
13. 
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 Figure 13. Streptavidin immobilisation technique chemical reaction. (Left) Reverse Reaction - N-
hydroxysuccinimide (NHS) within the heterobifunctional PEG compound reacts with the primary 
amines of the GM-CSF molecule forming a stable amide bond and releasing NHS. The GM-CSF-PEG-
Biotin conjugate is then introduced to a streptavidin pre-functionalised magnetic particle where a 
stable (spontaneous) bond is formed between the streptavidin and biotin groups. The red circle 
represents a magnetic particle functioned with streptavidin groups and having a mean diameter of 
2.8µm. (Right) Forward Reaction – The forward reaction involves a similar chemical process to the 
reverse reaction however, the GM-CSF molecule is first PEGylated before being conjugated to the 
streptavidin functionalised particle.  
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3.1.1.1.3 Solulink 
Solulink is a commercially available magnetic microparticle protein conjugation kit.  Proteins 
are immobilised by a quantifiable bond through modification of the protein using a 
proprietary chemical process illustrated in  Figure 14. 
 
 Figure 14. Solulink immobilisation technique chemical reaction. GM-CSF is modified to incorporate S-
HyNic by targeting the primary amines of the protein. The modified GM-CSF molecule is incubated 
with 4FB pre-functionalised magnetic particles in the presence of a catalyst (aniline). GM-CSF is 
specifically immobilised by the formation of a stable covalent bis-arylhydrazone bond. The black 
circle represents a magnetic particle functioned with 4FB groups and having a mean diameter of 
2.8µm. 
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3.1.1.1.4 Fibronectin 
The fibronectin immobilisation technique is a passive adsorption technique where proteins 
are passively adsorbed onto the fibronectin molecules through electrostatic interactions. 
This method is most similar to the natural immobilisation of growth factors and proteins in 
vivo by the extracellular matrix.  
 
 Figure 15. Fibronectin immobilisation technique chemical reaction. Fibronectin is incubated with plain 
magnetic particles (non-functionalised) to enable passive adsorption. GM-CSF is then immobilised 
by incubation with the fibronectin coated particles through passive adsorption. The blue circle 
represents a plain magnetic particle having a diameter of 2.0-2.9µm. 
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3.1.2 Cell Counting Methods 
To investigate the functional effects of immobilised growth factors (specifically the effects 
on cell growth rates in comparison to soluble growth factors), high resolution growth curves 
were required using a high-throughput cell counting assay. A number of cell viability assays 
are available, however as highlighted in  Table 6, the majority of current cell counting assays 
do not offer the high-throughput element required to construct high resolution cell growth 
curves. 
After evaluating the available cell counting methods, flow cytometry (i.e. the BD FACS Canto 
II) was selected as a high-throughput cell counting method that could achieve cell growth 
curves with a high degree of time resolution.  
3.1.3 Protein Quantification Methods 
 
3.1.3.1 Immobilised Proteins 
A custom quantification method was developed using flow cytometry and is described in full 
in  3.2.3. In brief, immobilised growth factors were incubated with fluorescently labelled 
antibodies and quantified from a standard curve using fluorochrome matched fluorescent 
standards. Molecules of equivalent soluble factor (MESF) values could be determined from 
fluorescence intensity.  
3.1.3.2 Soluble Proteins 
Concentrations of soluble growth factors were determined using the Luminex MAGPIX™ 
multiplex system as per the manufacturer’s protocol. Multiplex or singleplex kits were 
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purchased from R&D Systems. Media samples were stored at -80ºC, thawed at room 
temperature and vortexed directly prior to analysis.   
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 A comparison of widely used cell viability assays. The table shows that widely used assays are not high-throughput and therefore can not generate the high-resolution Table 9.
cell growth curves required to investigate the functional effects of immobilised growth factors.  
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3.2 Results 
The following results section evaluates the short-listed (refer to  section3.1.1.1) growth 
factor immobilisation techniques using a functional assay and aims to develop a 
quantification assay so that the potency of growth factors can be determined and the 
immobilisation method can be optimised.  
3.2.1 Development of a Functional Assay to Assess Biological Activity of Immobilised 
Growth Factors 
To investigate the biological activity of immobilised growth factors, a functional assay was 
developed consisting of a model (growth factor dependent) haematopoietic cell line to 
reduce the complexities involved in primary cell systems (i.e. donor variability and cell 
differentiation). The cell line is a Human erythroblast derived from leukaemia – TF-1 
Erythroleukemia.  
3.2.1.1   Activity of Soluble GM-CSF in a GM-CSF Dependent Cell Line. 
Since TF-1 cells proliferate dependently on Granulocyte Macrophage Stimulating Colony 
Stimulating Factor (GM-CSF) a dose-response assay of GM-CSF was performed in order to 
determine the dose required for the maximal biological response using an AlamarBlue® 
assay.  
Cell seeding density, growth factor incubation period, AlamarBlue incubation period and 
phenol red interference were predetermined in assay optimisation studies (results of the 
optimisation studies can be found in Appendix A). 
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 Figure 16 shows the dose-response profile of soluble GM-CSF in the TF-1 cell line. The 
maximal biological response was achieved with 2.3 ng/mL of soluble GM-CSF where the EC50 
was calculated at 0.25 ng/mL.  
The results from the dose-response assay are in agreement with the supplier QA results for 
the TF-1 cell line, where a recommended concentration of GM-CSF is 2-5ng/mL. To ensure 
that the maximum biological response was achieved across experiments, 5 ng/mL of soluble 
GMSCF was used in all future experiments as a positive control. 
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 Figure 16. Dose-response profile of soluble GM-CSF in a TF-1 cell line. The response profile shows that 
concentrations of 2 ng/mL and above provide the maximal TF-1 cell number after 48 hours of 
culture. The EC50 was calculated at 0.24 ng/mL. Data points represent the mean fluorescence 
intensity of a cell viability assay reagent - AlamarBlue (n=5±S.D).  
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3.2.1.2 Flow Cytometry for High Resolution Cell Growth Curves 
It was hypothesised that cell suspensions could be sampled and dispensed into a 96 well 
plate containing a cell fixative solution (2% final concentration paraformaldehyde), where 
the plate could later be analysed using high-throughput flow cytometry. Automated 
sampling and high-throughput analysis allows continuous sampling over a 24 hour period 
enabling high resolution growth curves to be constructed.  
Analysing a fixed volume of the wells at a fixed flow rate using flow cytometry would allow 
relative cell growth curves to be established between conditions by gating around viable 
cells on a standard forward v side scatter dot plot and obtaining an event count for that 
viable cell gate.  
To validate the gating strategy on flow cytometry, serial dilutions of viable TF-1 cells were 
performed and calculated viable cell counts were compared between flow cytometry and a 
standard automated membrane exclusion assay (acridine orange and DAPI; NC-3000, 
Chemometec).  
Viable cell counts displayed high correlation (R2=0.99) between those calculated using the 
custom flow cytometry assay and the automated cell membrane exclusion assay, across a 
wide range of cell densities; 1.5x103 cells/mL – 3.1x106 cells/mL  (see  Figure 17). 
The custom flow cytometry cell counting assay was carried forward in cell proliferation 
based assays to investigate the functional differences between soluble and immobilised 
growth factors. 
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 Figure 17. Flow cytometry event count correlates with membrane integral TF-1 cell count. A high 
correlation between viable cell count per mL (membrane exclusion method) and event count (flow 
cytometry) was observed (R-Sq = 0.99). Flow cytometry can be used as a high resolution cell 
counting method. Data points are representative of mean viable cells per mL and event count 
(n=5±S.D) 
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3.2.1.3  Optimisation of TF-1 Culture Conditions.  
The following experiments were performed to optimise the culture conditions of TF-1 cells 
in an automated stirred tank micro-bioreactor ambr™ 15 ( Figure 18). The ambr was chosen 
as a small scale model of a standard stirred tank bioreactor since it has been shown to scale 
well up to 200 Litres with CHO cell culture[102]. The aims of the optimisation studies were 
to prolong cell growth by reducing limiting factors of cell growth i.e. cell density, metabolic 
waste products, maintenance of pH, nutrient and growth factor supplementation. 
Optimisation of the culture conditions will enable good experimental control when the 
functional assay is used to evaluate the activity of immobilised growth factors.    
 
 Figure 18. The AMBR 15 with 24 micro-bioreactors. 
It was hypothesised that a bell shaped curve relationship would exist between cell seeding 
density and final density over a given duration; where low seeding densities would limit cell 
growth due to a lack of secreted paracrine factors and cell-to-cell contact and high cell 
seeding densities would limit final cell density due to medium exhaustion and induced cell 
death due to excessive contact inhibition [103]. 
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The optimal cell seeding density was investigated to determine the density for prolonged 
cell growth until media exhaustion. TF-1 cells were starved of GM-CSF for 24 hours prior to 
the experiment to prevent historic exposure of cytokines impacting the results of the assay, 
so that it is clear that the functional response is from the exposure of cytokines presented at 
t=0.  Figure 19 shows the effect of cell seeding density on cell growth over 96 hours until 
media exhaustion. A lag in cell growth was observed for the initial 22 hours of culture, this 
was due to the GM-CSF starvation for 24 hours before the beginning of the experiment (t=0). 
Cells entered log phases of growth following 22 hours, where each condition reached a 
different peak cell density before cell numbers decreased thereafter.   
Since all conditions reached different peak cell densities it was hypothesised that a factor 
other than final cell density was becoming inhibitory for cell growth (i.e. GM-CSF 
degradation, inhibitory paracrine signals or a build-up of toxic metabolic by-products).  
The effects of re-supplementing GM-CSF on TF-1 cell growth were investigated since it is 
recommended that GM-CSF be supplemented every 2-3 days.  Figure 20 shows cell growth 
was sustained for longer durations with GM-CSF supplementation where peak final cell 
densities were achieved at similar time-points for most conditions (approximately 100 hours) 
with the exception of the highest cell seeding density condition which peaked around 48 
hours ( Figure 21).  
Nutrient and metabolite analysis of spent media at 168 hours shows glucose concentrations 
decreased by 7% and 62% in 1.90x106 and 6.08x106 cells/mL cell seeding densities 
respectively. Glucose was found to be depleted in the four lowest seeding densities and >1.5 
g/L of glucose remained in the highest cell seeding density condition. In addition, the final 
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concentrations of glutamate and ammonium decreased linearly with an increase in seeding 
density.  
The nutrient and metabolite results show intermediate cell densities are dividing at a higher 
rate and therefore their metabolic demands are increased – the utilisation of more glucose 
coincides with increased production of lactate (via anaerobic respiration). 
It has been well documented that the hypoxic nature of the HSC niche is critical for cell 
proliferation and differentiation, therefore the effect of hypoxic conditions on TF-1 
proliferation was investigated[104]. Furthermore, phenol red can affect the regulation of pH 
in the AMBR bioreactor, thus phenol red free medium was used in this experiment[105].  
 Figure 22 and  Figure 23 show a general increase in cell growth with the absence of phenol 
red. Increased growth rates could be due to an inhibitory effect of phenol red on TF-1 cells 
or that the pH of the media was better controlled by the AMBR bioreactor (Phenol red 
interferes with the optical sensors that analyse media pH in the AMBR) . Additionally, the 
glutamine source was changed from L-glutamine to a more stable form (Glutamax) to 
prevent degradation into ammonia which could also be a cause of increased growth rates. 
In contrast to the literature, no differences in cell growth profiles were observed between 
21% or 5% dO2 for similar cell seeding densities[95].  
Similar growth rates were observed for the various seeding densities until approximately 72 
hours, with the exception of the highest seeding density (1x106 cells/mL).  A decline in cell 
growth is observed earlier in this experiment compared with the previous experiment, most 
likely due to faster cell proliferation rates and therefore media exhaustion.  
L-glutamine rapidly degrades into ammonia and pyrrolidone carboxylic acid in cell culture 
media [106], [107]. A dipeptide form of glutamine (L-alinine-L-glutamine, commercially 
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known as GLUTAMAX) is often used as a direct substitute to L-glutamine in cell culture since 
it is less prone to degradation. It was hypothesised that substituting L-glutamine with 
GLUTAMAX would increase cell growth by maintaining a stable concentration and reducing 
ammonia production.  
 Figure 24 shows that glutamax improves growth rates in the 2x104 cells/mL seeding 
densities in comparison to L-glutamine, particularly after 48 hours of culture but no 
significant differences were observed for higher seeding densities. 
Glucose depeletion and ammonium concentrations were shown to be limiting factors at the 
end of the culture period for conditions with GM-CSF supplementation. Conditions free of 
GM-CSF demonstrated no cell growth and therefore glucose was not metabolised. 
The series of experiemnts in this section have defined a well charactersied cell line culture 
system which will assist in evaluating the functional effects of soluble versus immobilised 
GM-CSF. Furthermore, experiments can be designed and conclusions drawn with the 
variables that affect growth limitations in mind at different cell densities.   
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 Figure 19.  Effect of TF-1 cell seeding density on cell growth until media exhaustion in a stirred tank 
bioreactor. Conditions show an initial lag period of 22 hours where cells enter a log period of 
growth thereafter (with the exception of the highest cell seeding density). Cell growth diminishes at 
various time points depending on initial seeding density with highest densities diminishing soonest. 
Optimal seeding densities for prolonged growth phases are between 4x104 – 5x105 cells/mL. Data 
lines are representative of mean smoothed data where an average of 3 time points were taken 
(n=2). Sampling occurred every 2 hours.  
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 Figure 20. Effect of TF-1 cell seeding density and GM-CSF replenishment on cell growth until media 
exhaustion in a stirred tank bioreactor. Top Graph - Exponential cell growth phase is significantly 
extended with GM-CSF replenishment; cells continue to grow after 150 hours without a medium 
exchange (3.16x104 cells/mL). Data lines are representative of mean smoothed data where an 
average of 3 time points were taken (n=2). Sampling occurred every 6 hours. Vertical dotted lines 
indicate time points of soluble GM-CSF replenishment. Bottom Graph - End-point nutrient and 
metabolite analysis of spent media identifies glucose depletion and metabolic waste products as 
limiting factors for cell growth at later stages of the culture period.  
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 Figure 21. Overlay of figure 19 and figure 20 showing that GM-CSF extends cell growth. GM-CSF 
utilisation is predominantly cell density dependent.  
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 Figure 22.   Effect of phenol red free media and dO2 on TF-1 cell growth until media exhaustion in a 
stirred tank bioreactor. Phenol red free media improves cell growth particularly in the mid stages of 
culture. Low concentrations of dissolved oxygen display no benefit for cell growth. Data lines are 
representative of mean smoothed data where an average of 3 time points were taken (n=2). 
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 Figure 23.  Overlay of figure 20 and figure 22 showing improved cell growth with the withdrawal of 
phenol red from cell culture media.  
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 Figure 24. Effect of glutamine source on TF-1 cell growth until media exhaustion in a stirred tank 
bioreactor. A) Cell growth is improved with glutamine supplemented as a stable dipeptide - 
Glutamax. Data lines are representative of smoothed data where an average of 3 time points were 
taken (n=2). B) Glucose was completely depleted except for conditions which showed no cell 
growth. Ammonia did not significantly differ between Glutamax and L-glutamine conditions. 
Columns show nutrient and metabolite concentration of spent medium at hour 120. 
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3.2.2 Selection of a Growth Factor Immobilisation Method 
The shortlisted immobilisation techniques were screened to assess their performance on 
key experimental outcomes which informed the selection of a single immobilisation 
technique. The selection criteria were: 
• Technical ease,  
• Cost,  
• Biological potency,  
• Reproducibility,  
• Clinical compliant (i.e. potential GMP grade reagents).  
The following series of experiments were performed in order to demonstrate the feasibility 
of immobilising growth factors in order to induce a functional response (in this case - cell 
proliferation) and to select the most suitable technique to carry forward into further 
experiments.   
3.2.2.1 Growth factor concentration 
The functional effects of four different protein immobilisation methods were investigated 
using the TF-1 functional assay developed previously (see section  3.2). Due to a problem 
with the flow cytometer, cell counts were determined using the NC-3000 method. In 
addition to the immobilisation method - GM-CSF concentration was also investigated for 
each of the methods to determine if surface concentration could be manipulated and if 
surface concentration had an effect on cell growth.  
 Figure 25 that shows a biological response was observed in two out of the four 
immobilisation techniques – Streptavidin and Fibronectin. The Streptavidin and Fibronectin 
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immobilisation techniques significantly (P=≤0.0001) induced cell proliferation in comparison 
to the negative control (GM-CSF free). The population doublings per day for the Streptavidin 
and Fibronectin conditions did not significantly deviate from the positive control (5ng/ml 
soluble GM-CSF) which has previously been shown to achieve the maximum biological 
response ( Figure 16). The stimulation of cell proliferation in the Streptavidin and Fibronectin 
immobilisation techniques provides strong evidence for the successful immobilisation of 
GM-CSF, since this cell line proliferates dependently on GM-CSF.  
No increases in population doublings were achieved using the Carboxylated and Solulink 
immobilisation techniques, where the mean population doublings demonstrated no 
deviations from the negative control condition (GM-CSF free). The failure of the Solulink and 
Carboxylated immobilisation techniques were likely methodology related as explained 
below: 
• Failure of Carboxyl method: The disulphide bonds of the GM-CSF molecule were 
targeted with TCEP to transform the bond into a thiol group, which would later 
spontaneously react with the maleimide group of the PEG linker in the carboxylated 
immobilisation technique ( Figure 12).  Disulphide bonds are critical for maintenance 
of the tertiary structure of proteins, thus disrupting disulphide bonds could have 
denatured the protein causing it to lose its function and hence cell proliferation was 
not induced[108].  
• Failure of Solulink method: Solulinks’ immobilisation technique is considered a single 
use kit. In this experiment the conjugation reagents were split into three equal parts 
to allow the conjugation of three different concentrations of GM-CSF where the de-
salting spin columns were re-used. It is likely that splitting those conjugation 
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reagents had altered the specific molarities (or volume) required for the conjugation 
reaction to take place and therefore the splitting of reagents will be avoided in 
future experiments.  
•  In addition, the streptavidin and fibronectin immobilisation techniques both 
included large protein molecules (Streptavidin = 52.8kDa; Fibronectin = 440kDa) 
within the GM-CSF conjugated bond whereas, the Carboxylic and Solulink 
immobilisation techniques contained short covalent bonds. Since the two methods 
that demonstrated functional activity, in culture, involved large protein linkers this 
supports the hypothesis that the steric presentation of GM-CSF has an important 
role to play in functional activity. Large protein linkers disperse the GM-CSF more 
than smaller chemical bonds on the particle surface and they introduce flexible 
bonds which may help in receptor accessibility and multiple growth factor-receptor 
complexes in turn having improved synergistic signalling effects.  
In general no significant differences in population doublings were observed by altering the 
concentration of soluble GM-CSF. This result could be due to two reasons. 1) The surface 
concentration is saturated at the lowest level of initial GM-CSF concentrations and further 
increases in GM-CSF concentration do not increase surface concentration or 2) The 
functional response is saturated at the lowest GM-CSF concentration. However there was a 
tendency for the population doublings to increase with increasing initial GM-CSF 
concentrations for the Streptavidin immobilisation technique. 
Quantifying the surface concentration would allow us to determine if the surface was 
saturated at lower GM-CSF concentrations. In addition, a series of particle concentrations at 
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fixed GM-CSF concentrations would assist in determining if the functional response was 
saturated.   
This experiment has demonstrated that a growth factor can be immobilised onto magnetic 
particle and retains its biological activity to stimulate a biological response (in this instance, 
cell proliferation).  
A following experiment was conducted to investigate the effect of particle concentration on 
cell proliferation as opposed to the previous GM-CSF concentration variable and to correct 
any methodological errors previously encountered. 
 Figure 26 illustrates that the Solulink and streptavidin conditions produced a statistically 
significant increase (P=≤0.0001; 4E5 particles/mL) in population doublings compared with 
the negative control (GM-CSF free). Albeit lower than the positive control.  
The streptavidin immobilisation technique performed less well in comparison to the 
previous experiment, with a 1.75 fold reduction in mean population doublings between 
experiments. This observed difference in response is likely due to different culture 
conditions and batch variation of the Streptavidin particles and (or) control over final 
particle concentration. The culture plate conditions differed from the first experiment by 
the use of a deep well plate (1mL well volume) as opposed to a standard 96well plate (max. 
well volume 300 µL).  
Larger differences in functional response were observed by altering particle number as 
opposed to GM-CSF concentration (in the previous experiment). This suggests that 
functional response is saturated at the surface concentrations previously used.  
The functional response to the fibronectin particles was unable to be investigated in this 
experiment due to particle aggregation following incubation of the plain particles with 
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fibronectin. Also, the carboxylated immobilisation technique was not investigated due to 
loss of particles during washing stages.   
To further investigate the properties of immobilised growth factors using magnetic particles, 
the Streptavidin immobilisation method was selected to carry forward because it met the 
criteria listed in section  3.2.2. 
 
 
 Figure 25.  Screen of immobilized GM-CSF prepared using four different conjugation methods and three 
different GM-CSF-biotin concentrations. Significant TF-1 cell growth was achieved in streptavidin 
and fibronectin preparation methods. Carboxylated and solulink conditions were not statistically 
different from the negative control (GM-CSF free). Higher GM-CSF-Biotin concentrations induced 
the highest population doublings per day in the streptavidin and fibronectin conditions. Columns 
represent mean population doublings per day (n=3±S.D). **** = P ≥ 0.001 
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 Figure 26. Functional screen of immobilized GM-CSF prepared with two different conjugation methods 
and three final bead concentrations. Statistically significant increases in population doublings were 
seen for the two highest bead concentrations in the solulink and streptavidin conditions.  The 
lowest bead concentration conditions did not induce cell proliferation and the plain particle 
condition exhibited similar response to the GM-CSF free condition demonstrating no non-specific 
binding of GM-CSF. Columns represent mean population doublings per day (n=3±S.D). **** = P ≥ 
0.001 
 
3.2.3 Development of a Quantification Assay 
As discussed in the introduction, many quantification methods are not applicable to 
immobilised growth factors. Consequently, this section explores the use of flow cytometry 
and fluorescent reference standards as a specific method for quantification of immobilised 
growth factors. A quantification method will allow a direct comparison to the relative 
potencies of growth factors in immobilised or soluble formats and it will also allow the 
effects of changing variables within the immobilisation reaction to be investigated in order 
to optimise surface concentration.   
It was hypothesised that immobilised growth factors could be quantified with fluorescently 
labelled antibodies and fluorescent reference standards using flow cytometry. An overview 
of the flow cytometry quantification assay is illustrated in  Figure 27. 
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The following experiment was performed in order to determine if the sensitivity of flow 
cytometry was sufficient to quantify immobilised GM-CSF.  Figure 28 shows small increases 
in fluorescence intensity between the positive stained sample and IgG control. A net 
increase in the geometric mean of fluorescence was 17 and 15 for technical replicate 1 and 
replicate 2 respectively. Net fluorescence was converted to 246 and 217 Molecules of 
Equivalent Soluble Factor (MESF).  
A Students t-test was conducted in order to determine if the small differences in fluoresce 
between the IgG controls and positively stained sample were within the noise of the 
measurement system or whether this was representative to immobilised GM-CSF. Statistical 
analysis of the MESF values were shown to be significantly different from the IgG controls 
(P<0.05).  
The reported biotin binding capacity of the particles were 2x10-4 grams per particle. 
However, the calculated mass of immobilised GM-CSF was an average of 0.005 femtograms 
per particle. However the maximal functional response was achieved with 0.005 fg/particle 
at 2x105 particles/mL  (or a total of 1.08±0.10pg/mL immobilised GM-CSF).  
A reduced concentration of GM-CSF could be due to multiple biotins binding per GM-CSF 
molecule (maximum of 6 biotins per GM-CSF), potentially reducing the maximum binding 
capacity 6 fold (3.3x10-5 grams per particle) and this could be reduced further by steric 
hinderance of large GM-CSF-PEG conjugates.  
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 Figure 27. Exemplar work flow for the quantification of immobilised proteins using flow cytometry. 
Molecules of equivalent soluble factor (MESF) are calculated from fluorescence intensity and used 
to calculate a mass of growth factor per particle. 
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 Figure 28. Quantification of immobilised GMSCF using flow cytometry A) Fluorescence histograms of igg 
control and positively stained samples. B) Statistical significance of calculated MESF values between 
IgG controls and positively stained samples. C) Functional response as determined by the NC-3000 
cell counting method. *= P<0.05 ( n=2±S.D). 
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3.2.3.1 Optimising the flow cytometry quantification assay 
The entire immobilisation and quantification process was mapped out using a flow diagram 
and fishbone diagram ( Figure 29 and  Figure 30) in order to highlight variables which are 
most likely to impact on the final surface concentration and quantifiation accuracy of 
immobilised GM-CSF. Highlighting those variable that have an impact on suface 
concentration or accuarcy of the quantification method could then be controlled or 
optimised in future experiments.  
Antibody (Ab) concentration, particle concentration and surface concentration of iGFs will 
have an impact on the calculated iGF concentration. The initial quantification assay was 
performed using an unknown amount of particles and a standard 1:10 ab dilution was used 
as a final concentration during incubation (with no prior ab titration). Since the iGF 
concentration in the initial quantification assay was lower than expected – it suggests that 
optimising or controlling all three factors could improve the assay accuracy.  Therefore a 
series of particle concentrations and ab concentrations were analysed.  
 Figure 31 shows antibody saturation at >50 µL of antibody per mL of stain buffer. Previously 
only 10 µL of antibody was used which gave move than a 6 fold difference in the calculated 
immobilised GM-CSF per particle.  
The streptavidin particles have a certificate of analysis (CofA) which reports a biotin binding 
capacity i.e. the mean quantity of biotin the particles can bind as determined by the 
manufacturers assay. However, even with Ab titration this is still significantly less than the 
reported biotin binding capacity and may suggest that there is further optimisation required 
from the immobilisation method itself. In addition, the quantification assay was shown to be 
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sensitive to particle number. A linear increase in surface concentration was observed with 
decreasing particle numbers.  
There is a requirement for high ab concentrations to ensure the ab is in excess of iGF for 
accurate quantification of iGFs. Using high concentrations of ab would become a very 
expensive assay, particularly if multiple iGFs were quantified simultaneously. There are 
further means in which the antibody concentration could be reduced for example; by 
lowering the staining volume, increasing incubation times and ensuring that there is 
sufficient mixing during ab incubation. However, these steps would introduce longer process 
times, more process steps, and increased assay variation/error – all undesirable traits for a 
manufacturing process. Therefore, it was decided to allow an event count that would be 
considered sufficient for flow cytometry analysis and to reduce the quantity of antibody 
required that the number of particles for the assay would be fixed at 2x105 particles in a 
staining volume of 100µL.  
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 Figure 29.  Flowchart showing the growth factor immobilisation and quantification process highlighting 
areas of risk (blue circles) which could impact the efficacy of the immobilisation process or 
functionality.  
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 Figure 30. Fishbone diagram of immobilisation and quantification method showing the 
variables that impact reproducibility and accurate quantification of the immobilisation method. 
Numbers in green circles are references to figures in this thesis where the variables were tested. 
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 Figure 31. Optimisation of quantification assay parameters A) Optimisation of antibody concentration B) 
Effect of particle concentration at a fixed antibody concentration. Data points show mean 
immobilised GM-CSF per particle ± S.D (n=2).  
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3.3 Discussion 
This chapter aimed to develop a novel and scalable protein immobilisation method using 
magnetic microparticles.  
In order to screen and evaluate immobilisation techniques, a functional assay was 
developed using a growth factor dependent cell line. The culture conditions of the cell line 
were optimised before screening the immobilisation methods to ensure that maximum 
sensitivity could be achieved in the assay.  
Four short-listed immobilisation methods were screened by assessing their biological 
activity in the functional assay. The streptavidin immobilisation technique was carried 
forward because it consistently showed good functionality and met the desirable criteria 
such as: technical ease, low cost, reproducibility and being clinical compatible. Efforts to 
correct the failure of other immobilisation techniques could have been carried out, however 
in the interests of pursuing the experiments to look at functional effects (and because the 
results of the streptavidin method were promising) a decision was made to take forward the 
streptavidin method so that the functional effects and process benefits could be 
investigated. 
To determine the potency of immobilised growth factors in relation to their soluble 
equivalents and in order to optimise the surface concentration of immobilised growth 
factors, a quantification assay was developed using flow cytometry since current protein 
quantification methods were not suitable.  
Process mapping and tools such as fish-bone diagrams have enabled the identification of 
variables in the immobilisation process which may result in irreproducibility and inaccurate 
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quantification of immobilised growth factors. Reducing the variation in the growth factor 
immobilisation method will enable consistent cell growth between experiments.  
The methods developed in this chapter enabled the properties of the immobilisation to be 
investigated further and also allows the method to be optimised further before applying to 
primary cell culture systems.   
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4 Functional Properties of Immobilised Growth Factors 
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4.1 Introduction 
In the previous chapter it was demonstrated that a single growth factor (GM-CSF) retained 
its biological activity once immobilised onto magnetic microparticles as demonstrated in a 
static functional assay.  
Soluble growth factors (sGF) will diffuse down a concentration gradient in static culture 
systems; whereas iGFs have a fixed locus (iGFs will settle) leading to potentially 
heterogeneous exposure of individual cells.  
A major advantage of the immobilisation method means the particles have the potential to 
be used in agitated (scalable stirred tank) cell culture platforms. Achieving controlled cell 
fate outcomes from immobilised growth factors (iGFs) is dependent on a suitably well mixed 
system and that the cell to iGF interaction scales predictably with scale of the manufacturing 
platform.  
Stirred tank bioreactors are well characterised and bode well for the manufacture of 
haematopoietic cell therapies due to the non-adherent nature of the cells and such culture 
formats have extensive literature supporting control of culture conditions and scalability 
[96], [98]. 
This chapter aims to explore the scalability of the GF immobilisation method developed in 
the previous chapter, demonstrate the process benefits the method may entail (e.g. the 
ability to re-use growth factors) and to demonstrate additional functional benefits.  
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4.2 Results 
The following results section will look at the scalability of the immobilisation technology, 
look at optimising the surface concentration of multiple clinically relevant GFs, and 
demonstrate the functional and process benefits of iGFs.  
4.2.1 Scalability of Immobilisation method - Proof of Concept  
The aim of this experiment was two-fold; 1) to demonstrate that the immobilisation 
technology is scalable in stirred tank bioreactors and 2) that the particles (and therefore 
growth factors) could be retained and recycled during a media passage and continue to 
elicit a biological response thereafter.  
 Figure 32 shows the growth curves of TF-1 cells over the course of 6 days with a media 
passage performed at day 3. Growth curves were determined using the Vicell cell counting 
method and magnetic particles were retained using method  2.9.2. The growth curves for 
the positive control and immobilised GM-CSF condition were comparable for the first three 
days of culture with population doublings of 2.7 and 2.5 respectively over the three days.  
Following a media exchange at day 3, cell growth diminished for the immobilised GM-CSF 
condition whereas the positive control continued to grow in log phase.  
Diminished cell growth could be due to a decline in immobilised GM-CSF activity or that the 
retention of particles was not efficient during the media exchange process; the sensitivity of 
cell growth to particle concentration was demonstrated in the previous chapter. To ensure 
particle retention is efficient, in future experiments a magnet will be placed onto the side of 
vessels whilst slowly aspirating cell suspensions to minimise particle loss.  
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 Figure 32. Functional activity of immobilised GM-CSF in a stirred tank culture system. A) Immobilised 
GM-CSF induced TF-1 cell growth at equal levels to the positive soluble GM-CSF control conditions 
for up to 3 days in culture. B) Following a media passage at day 3 and a cell reset to a seeding 
density of 2x105 cells/mL the functional response of immobilised GM-CSF was reduced where cell 
growth plateaued at day 5. Data points represent viable cells per mL (n=1). 
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4.2.2 Effects of immobilised growth factor surface concentration 
 
It was hypothesised that different surface concentrations and total surface area of 
immobilised growth factors would have distinct functional effects. Immobilised 
concentration was varied in two ways; 1) by changing the surface concentration by using an 
unconjugated PEG molecule (PEG 10,000) during the preparation of the growth factors for 
competitive binding and 2) by varying the concentration of particles at a fixed surface 
concentration. The rationale for changing surface concentration was due to the reported 
functional differences between ligand spacing as reported in the literature [109].  
 Figure 33 shows cells did not grow for the initial  ~20 hours of culture for all conditions, due 
to the starvation of GM-CSF for 24 hours before t=0. Following ~20 hours of culture, cells 
began to proliferate exponentially for the positive soluble control (5 ng/mL of soluble GM-
CSF) and the two highest immobilised GM-CSF concentrations (total concentration, blue and 
purple conditions) where the positive soluble control and 0.092 fg/particle (2x105 
particles/mL) concentrations exhibited similar growth curves up to 50 hours of culture. 
Intermediate cell growth was induced with the 0.092 fg/particle (2x104 particles/mL) and no 
cell growth was observed for the lowest two immobilised GM-CSF concentrations.  
Notably, conditions with similar total concentrations of immobilised GM-CSF but different 
surface concentrations (conditions 3 and 5) exhibited opposing functional effects, where 
lower surface concentrations failed to induce cell growth. This is in line with the literature in 
that that there may be optimal ligand spacing for the desired functional response[109].  
In this experiment surface concentration of immobilised GM-CSF was controlled by the use 
of an unconjugated PEG molecule (PEG 10,000) which was hypothesised to competitively 
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bind with biotinylated GM-CSF onto the streptavidin particles. Surface concentration could 
be varied with the use of an unconjugated PEG molecule; however the surface 
concentration was unpredictable in this experiment. Conditions 4 and 5 were predicted to 
be 10% concentration of conditions 2 and 3, however were closer to 1% of the 
concentration. It is possible that the PEG 10,000 sterically blocked the binding of 
biotinylated GM-CSF to give lower vales than predicted as illustrated in  Figure 33B.  
It was then hypothesised that surface concentration could be controlled by varying the 
molar concentration of PEG during the conjugation stage. Until now, it was calculated that 
PEG was used at an 8000 fold excess to GM-CSF during conjugation. 8000 fold excess was 
used because this was the re-constitution concentration recommended by the 
manufacturer of the PEG and an equal PEG:GF volume was kept the same to ensure 
sufficient mixing volumes. The high PEG excess could be decreasing the reaction efficiency 
by a number of ways: 
 1. Free biotin will competitively bind with biotinylated growth factor for streptavidin 
ligands on the particles. The reaction will favour immobilisation of free biotin over 
PEGylated growth factor. 
2. An excess of free biotin will also increase the number of PEG molecules per growth 
factor reducing its effectiveness in two ways: 
• More PEG molecules per growth factor will decrease its biological potency by coating 
and disrupting its ability to bind to the growth factor receptor on the cell surface. 
• One growth factor with multiple PEG molecules has the potential to “blanket” coat 
multiple streptavidin ligands, therefore reducing the quantity of immobilised 
PEGylated growth factor molecules. 
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It was anticipated that biotin–PEG2000NHS in excess of a 1:1 ratio with target lysine would 
result in free-biotin being carried forward to competitively blank streptavidin on the 
particles and therefore reduce GF-biotin bound to the particles.  
A Biotin-PEG2000-NHS below a 1:1 ratio would result in the number of biotinylated GFs 
available during the particle binding step would become a limiting factor. It was therefore 
hypothesised that a 1:1 molar ratio of PEG:GF would result in the highest surface 
concentration of immobilised growth factor.  
In the next chapter the growth factor immobilisation technology will be used for proof of 
concept in a primary cell model culture system – expansion of umbilical cord derived HSCs. 
With this is mind, three growth factors were chosen for their use in the maintenance of HSC 
and progenitor populations. 
 Figure 34 shows that the surface concentration of three different growth factors could be 
controlled by altering the PEG:lysine ratio. As hypothesised, for each of the three growth 
factors the optimal PEG:lysine ratio was 1:1.   
Maximum mean surface concentrations were 2.5, 1.1 and 0.7 fg/particle for GM-CSF, SCF 
and TPO respectively. The maximum surface concentration was not correlated to the 
growth factor’s molecular weight (molecular weight for GM-CSF, SCF and TPO are 14, 18.6 
and 18.6 kDa respectively) or lysine number (Lysine number for GM-CSF, SCF and TPO are 7, 
14 and 5 respectively). It is likely that the ‘availability’ of lysine residues has an impact on 
the maximum surface concentration. 
It was hypothesised that the surface concentration of immobilised GF could be manipulated 
by varying the absolute concentration of biotin–PEG2000-NHS and GF during GF 
biotinylation, at a fixed molar ratio of 1:1 biotin-PEG2000-NHS to lysine residues. In previous 
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experiments the GF concentration during the Biotinylation stage has been 10 µg/mL (10 
µg/mL is the recommended concentration for reconstitution of lyophilised GFs as per 
manufacturer guidelines). 
 Figure 35 shows a sigmoidal relationship between soluble GF-biotin concentration and 
immobilised GF concentration with an R2 of 0.98 for both GM-CSF and SCF. The mechanism 
underpinning the sigmoidal relationship is likely to be NHS degradation (via hydrolysis) at a 
constant rate and a rate of NHS binding with GF which is proportional to reagent 
concentration. 
In contrast with the previous experiment – the highest concentration of immobilised SCF 
was approximately 3 times higher than GM-CSF at 200 µg/mL of soluble GF-Biotin 
concentrations..  
50 µg/mL of soluble GF-biotin was taken forward into future experiments primarily for cost-
effectiveness and because functional responses are likely to be saturated above this taking 
into account the results from previous experiments.  
A standard reaction time of 2 hours has been implemented for the Biotinylation reaction 
(see previous chapter)  in line with the literature, however it was hypothesised that 
immobilised GF concentrations could be increased by increasing the duration of the 
Biotinylation reaction [101].  
 Figure 36 shows the results of two reaction durations for SCF Biotinylation at two SCF-biotin 
concentrations. As expected, a 2 fold increase in SCF-biotin concentration increased the 
subsequent immobilised surface concentration 2 fold, from ~3 fg/bead to ~6 fg/bead. 
Surprisingly, increasing the reaction duration from 2 to 4 hours decreased the immobilised 
surface concentration slightly for both SCF-biotin concentrations. This is because the biotin-
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PEG molecule is dissolved in DMSO to prevent hydrolysis of the NHS terminal group. When 
the biotin solution is mixed with the GF at room temperature for Biotinylation – the DMSO 
denatures the α-helix of proteins at high concentrations and therefore it is likely that the 
immobilised GF is denatured to such an extent that the antibody cannot recognise the GF 
epitope [110], [111].  
Consequently, a 2 hour reaction period was implemented for future experiments to limit 
denaturation of immobilised GFs.  
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 Figure 33. The effect of surface concentration and surface area of immobilised GM-CSF on TF-1 growth 
in a stirred tank bioreactor. A) Growth curve of TF-1 cells in a stirred tank bioreactor in response to 
different surface concentrations and different bead concentrations of immobilized GM-CSF. The 
graph illustrates that functional response is reduced by one quarter with a log decrease in bead 
concentration (conditions 2 & 3). In addition, functional response may cease to exist when total 
immobilized GM-CSF is equal but surface concentrations are different (conditions 3 & 5). Data lines 
are representative of mean smoothed data where an average of 3 time points were taken (n=2). B) 
Schematic of steric hindrance using PEG10K to modulate surface concentration of immobilised GM-
CSF 
A 
B 
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 Figure 34. The surface concentrations of three growth factors were controlled by regulating the NHS-
(PEG)n-Biotin (Biotin) molar excess during step 1 of the immobilization reaction. Maximum surface 
concentrations were achieved with a 1:1 Biotin to Lysine molar ratio for each of the growth factors 
investigated (n=3 mean ± S.D). 
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 Figure 35. The effect of soluble GF-biotin concentration at optimal GF:biotin molar ratios were 
investigated to regulate the surface concentration of immobilized growth factors. A sigmoidal 
relationship between soluble GF-biotin and iGF concentration for (i) GM-CSF and (ii) SCF (n = 3 
mean ± SD). 
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 Figure 36. Reaction duration for SCF Biotinylation. A 2 hour reaction period provides maximum 
immobilised SCF concentrations following subsequent immobilisation. Data points represent mean 
femtograms of immobilised SCF per bead (n=3±S.D). 
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4.2.3 Functional Properties of immobilised Growth Factors 
Now the immobilisation method has been established and various methods for controlling 
surface concentrations of immobilised GFs has been demonstrated, the following series of 
experiments aimed to investigate the functional differences and processes benefits of GF 
immobilisation.     
A method for maximising and manipulating surface concentrations of growth factors was 
demonstrated in the previous section by altering the PEG molar concentration relative the 
lysine content of the growth factor. The functional activity of a range of iGM-CSF 
concentrations could therefore be investigated in vitro.  
 Figure 37A shows iGM-CSF created at a range of very low surface concentrations (0.008-0.09 
fg/bead) stimulated a linear increase in growth rate with a logarithmic increase in particle 
concentration, matching the soluble response at approximately 1x105 particles/mL at 0.09 
fg/particle or 0.009 ng/mL. 
 Figure 37B shows the conversion of the different particle concentrations and surface 
concentrations into total iGF presented per mL, allowing the calculation of a single dose 
response. This indicated a maximal immobilized dose response of approximately 1-10 
pg/mL, some 3 orders of magnitude more potent than the soluble equivalent. The formation 
of a relatively unified dose response curve from a range of different surface and particle 
concentrations suggest modulation of either surface concentration or particle number can 
be used to alter concentration of presented GF to a similar degree. 
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 Figure 37. (A) The response of TF-1 cells to a range of immobilized GM-CSF surface concentrations and 
particle concentrations were investigated. The maximum soluble response was achieved with 1x105 
particles/mL at a surface concentration of 0.09 fg/particle (B) Particle concentration and surface 
concentration was converted to total immobilized GM-CSF/mL to construct a single dose-response 
curve. The maximum immobilized response is achieved with 10 pg/mL of immobilized GM-CSF 
(n=3). 
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4.2.4 Recycling immobilised GM-CSF 
Since immobilised growth factors can be manipulated independently of the media bulk it 
was hypothesised that immobilised GM-CSF could be retained upon a media change. The 
functional stability of iGM-CSF was tested by culturing TF-1 cells with a single set of GM-CSF 
coated particles magnetically retained through serial bulk medium changes in a static well 
plate system.  
 Figure 38 shows the growth curve of TF-1 cells in static culture over 192 hours with a media 
passage every 48 hours. A positive control was treated with a media exchange containing 
sGM-CSF every 48 hours; a negative control had no GM-CSF. The graph shows the cell 
growth rate for the iGMSCF and sGM-CSF conditions were equivalent for the experimental 
duration of 192 hours with three media exchanges where approximately 2 population 
doublings occurred every 48 hours.  
The surface concentration of iGM-CSF was quantified at 1.56 fg/particle or 0.3 ng/mL at 
2x105 particles/mL – an order of magnitude lower than required for the soluble equivalent. 
The quantity of iGM-CSF used in this experiment was equivalent to a 94% decrease in total 
GF required to stimulate the maximal biological response. Including the three media 
changes the immobilized culture used 1.5% of the GF over the 192 hours relative to the 
soluble control. 
It was hypothesised that soluble GM-CSF degrades at a greater rate than iGM-CSF in line 
with literature[112], [113]. The concentrations of soluble GM-CSF were investigated over 96 
hours during static TF-1 culture in two different cell seeding densities (2x104 and 2x105 
cells/mL).  Figure 39 shows that GM-CSF concentrations remained stable at cell seeding 
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densities of 2x104 cells/mL, whereas concentrations of GM-CSF decreased by 33% at cell 
seeding densities of 2x105 cells/mL.  
The results suggest that degradation is likely catalysed by paracrine factors (e.g. proteases) 
and highlights the need for re-supplementation of soluble growth factors to maintain 
constant concentrations for optimal cell growth.  
 
 
 
 Figure 38. The effects of a single dose of immobilized GM-CSF (0.3 ng/mL) retained throughout the 
culture period was investigated in comparison to a soluble control (soluble GM-CSF was replaced 
every 48 hours at media change – vertical dashed lines). The cell growth rate for the immobilized 
and soluble GM-CSF conditions were equivalent for the experimental duration of 192 hours over 
three media exchanges (n=2±S.D). 
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 Figure 39. Degradation of soluble GM-CSF is cell density dependant. The graph illustrates stable GM-CSF 
concentrations at lower cell seeding densities over a 96 hour culture period. In contrast, GM-CSF 
concentrations decrease by ~33% over 96 hours with higher cell seeding densities. Data points 
represent mean concentration of GM-CSF in cell supernatant as determined by Magpix™ analysis 
(n=2). 
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4.2.5 Transient exposure of iGM-CSF 
The immobilised growth factor technique was shown to elicit a full functional response in a 
growth factor dependent cell line in a stirred tank bioreactor. An impeller speed of 350 rpm 
in previous experiments shows that very short collision times are required between the 
receptor and growth factor in order to initiate the signalling cascade – enzyme-substrate 
interactions have been reported as short as 50 ms-1 [114]. Therefore it was hypothesised 
that a continuous exposure to growth factors is unnecessary, and could even be 
unfavourable for cell growth due to receptor desensitization[113–115].   
 Figure 40 shows the growth curve of TF-1 cells in response to different exposure durations 
to immobilised GM-CSF.  
Cell growth was maintained for 36 hours in all conditions containing GM-CSF in both 
immobilised (0.5 hours and continuous exposure) and soluble form. Following 36 hours cell 
death occurred likely due to media exhaustion (i.e. glucose depletion as seen in the previous 
chapter) since a media change was not performed. The negative control displayed growth 
up to ~20 hours due to pre-historic culture with soluble GM-CSF.  
Interestingly, the 0.5 hour exposure to iGM-CSF achieved approximately the same response 
(~1 population doubling at hour 36) as the continuous exposure to iGM-CSF and the positive 
control. This suggests that continuous exposure to iGM-CSF is unnecessary for a full 
functional response. Sufficient particle removal was shown by flow plots in  Figure 41 and 
continued cell growth in the 0.5 hour condition was therefore not due to particle carry-over.  
It was then hypothesised that soluble GM-CSF does not induce the same functional 
response due to a more dilute localised concentration.  
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 Figure 42 shows the growth response of TF-1 cells after transient exposure to soluble GM-
CSF in static culture. The graph shows that an equivalent response (~-0.7 PDs/day) for 0.5 
hour exposure and the GM-CSF free condition, whereas continuous exposure resulted in 
~1.2 PDs/day.  
This experiment highlights the distinct functional responses immobilised and soluble growth 
factors have; this is likely due to the differences in localised surface concentrations – where 
immobilised growth factors can initiate receptor clustering for magnified stimulation of cell 
signalling[85], [117].  
In final proof of concept experiments, the process benefits (ability to recycle iGFs during a 
media exchange and benefits of transient exposure) of the immobilisation method were 
demonstrated. 
 Figure 43A shows the growth curve of TF-1 cells in response to iGM-CSF and sGM-CSF with 
either transient exposure (6 hours) or continuous exposure with two media changes 
performed at 48 hours and 96 hours where particles were recycled. sGM-CSF was 
replenished at 5 ng/mL after a media change for the soluble positive control and a negative 
control was GM-CSF free. iGM-CSF was quantified at 1.06 fg/particle (0.2 ng/mL).  
Equivalent growth rates were observed for the positive control and iGM-CSF continuous 
exposure condition for the initial 24 hours of culture. Following a media passage at 48 hours 
the positive control continued to grow exponentially reaching a cumulative population 
doubling of ~5.8 at 120 hours, whereas the iGM-CSF continuous exposure condition 
unexpectedly peaked at 3 cumulative population doublings at 48 hours and levelled-off for 
the remainder of the culture period.   
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Diminished performance in the iGM-CSF continuous exposure condition was thought to be 
caused by particle loss during the initial media change at 48 hours.  Figure 43C shows cell 
suspensions were sampled every ~3 hours and analysed using flow cytometry. Counting 
particles using flow cytometry showed a decrease in particle numbers over time, where half 
of the particles were removed before the first media passage and the majority of the 
remaining particles were lost after the 48 hour media change.  Particle loss was attributed 
to static interaction with the pipette tips as shown in  Figure 43B.  
Exponential cell growth was observed for 6 hour exposure period for iGM-CSF and sGM-CSF 
for ~36 hours, where the iGM-CSF condition peaked at approximately 1 cumulative 
population doubling in contrast to the soluble 6 hour exposure condition which peaked at 
approximately 0.5 cumulative population doublings. The results suggest an amplified 
response is achieved with iGM-CSF with a short exposure period in comparison to its soluble 
counterpart. 
In order to demonstrate that the immobilisation technique is not a slow-release mechanism 
for iGFs, media supernatant was sampled and analysed over the duration of the culture 
period using ELISA.  Figure 44 shows that no soluble GM-CSF was present in the iGM-CSF 
conditions over the culture period, providing assurance that the functional response is due 
to the immobilised GM-CSF solely. Effective removal of sGM-CSF was achieved in the 6 hour 
soluble GM-CSF condition and the positive soluble control showed a 50% decrease in 
concentration from 48 hours to 120 hours.  
In order to minimise particle loss the previous transient exposure experiment was repeated 
but with less frequent sampling points.  Figure 45A shows TF-1 cells responded equivalently 
to continual exposure of both sGM-CSF and iGM-CSF over the 120 hour culture period under 
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stirred conditions. A total of ~4 population doublings was achieved over 120 hours with the 
continuous exposure conditions, with an initial lag time of 24 hours. 
At sequential time intervals (2,4,8 and 20 hours) after initiation of culture, GF was 
withdrawn to determine if stimulation and decay of cell growth was equivalent for GM-CSF 
in both soluble and immobilized forms. Continued cell growth was observed for a significant 
time period after removal of sGM-CSF or iGM-CSF, however the duration and magnitude of 
growth was dependent on time of exposure and form of presentation ( Figure 45B). Cell 
growth measured at 50 hours showed a significantly (P = 0.01–0.05) higher response had 
been achieved with short exposure (2 and 4 hours) to iGM-CSF compared to equivalent 
short exposure to sGF, showing a heightened response to immobilised GM-CSF. 
Similarly, cell numbers continued to significantly increase (P ≤ 0.05) for a longer period 
after a short exposure (2 and 4 h) to iGM-CSF compared to the equivalent exposure to sGM-
CSF ( Figure 45C), showing immobilised GM-CSF initiates a longer lasting signalling potential.  
Flow cytometry analysis of cell suspensions over the duration of culture show efficient 
particle removal, and therefore sustained growth in transient iGM-CSF conditions was not 
attributed to residual particles ( Figure 46).  
iGM-CSF concentrations were quantified at 1.96 fg/particle or 0.4 ng/mL (2x105 
particles/mL) which equates to a 96% reduction in GF requirements for the continuous 
culture conditions (2 x 5 ng/mL supplements for the continuous soluble control). 
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 Figure 40. Effects of GM-CSF exposure period on functional response in stirred culture.  Growth curve of 
TF-1 cells in response to short exposure periods of immobilised GM-CSF in a stirred tank bioreactor. 
A 0.5 exposure period exceeds the functional response of positive control where faster growth 
rates were also achieved. Continuous exposure provides no benefit and may have negative effects 
on cell growth (n=2). 
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 Figure 41. Particle counts as determined by flow cytometry for immobilised GM-CSF conditions shows 
sufficient particle removal after 0.5 hours and maintenance of particles  in the continuous condition 
(n=2). 
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 Figure 42. 30 minutes transient exposure of soluble GM-CSF elicits no functional response in TF-1 cells 
(n=3 ±S.D).  
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 Figure 43. Effects of growth factor exposure period and recycling of immobilised GM-CSF in stirred 
culture. (A) Growth curve of TF-1 cells in response to continuous and 6 hour exposure periods of 
immobilised and soluble GM-CSF. The graph shows continuous exposure to immobilised and 
soluble GM-CSF produce identical functional responses. 6 hour exposure periods produce short 
periods of growth where the immobilised GM-CSF condition produced faster growth rates than the 
soluble counterpart. Diminished cell growth following 36 hours of culture was due to significant 
bead loss. (B) Beads were removed from culture by static interaction with pipette tips during 
sampling of the cell suspension (C) Analysis of media samples shows no leaching of immobilised 
GM-CSF across the entire culture period. Effective removal of soluble GM-CSF in the 6 hour 
exposure condition was demonstrated. In addition, soluble GM-CSF degraded by ~50% from hours 
48-120 (n=2).   
A 
B C 
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 Figure 44. Analysis of media samples shows no leaching of immobilised GM-CSF across the entire culture 
period. Effective removal of soluble GM-CSF in the 6 hour exposure condition was demonstrated. In 
addition, soluble GM-CSF degraded by ~50% from hours 48-120 (n=2).   
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 Figure 45. Functionality, stability, and manipulation of immobilized GM-CSF in stirred tank bioreactors 
and effects of transient exposure to growth factor. (A) The effects of immobilized and soluble GM-
CSF exposure time on subsequent TF-1 cell growth rates were investigated in an agitated scalable 
cell culture bioreactor. Identical cell growth rates were achieved with continuous exposure to 
immobilized and soluble GM-CSF (n=2±SD). Vertical dashed line represents the time of a full media 
passage and cell reset to initial seeding density. (B) A comparison of cell growth rates at a single 
time-point from Figure 45A (50 hours) for immobilized and soluble GM-CSF were investigated. Cell 
growth was significantly increased at 2 and 4 hours of exposure to immobilized GM-CSF when 
compared to soluble GM-CSF (n=2±SD). Single asterisks represents a P value of 0.01-0.05. (C) The 
period of sustained cell growth following growth factor removal was calculated from Figure 45A. A 
significant increase in the sustained cell growth was achieved with 2 and 4 hours of exposure to 
immobilized GM-CSF (n=2±SD). Single asterisks represents a P value of 0.01-0.05. 
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 Figure 46. Representative flow cytometry plots indicating efficient particle removal and sustained cell 
growth in transient iGM-CSF conditions was not due to residual particles.  
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4.3 Discussion 
Studies for numerous cell and gene therapies have shown that increasing cell numbers are 
correlated with good clinical outcomes [45]. In order to produce the required cell numbers, 
cell and gene manufacturing processes are likely to move towards scalable cell culture 
bioreactors such as stirred tank bioreactors. Therefore, the growth factor immobilisation 
technology developed in the previous chapter was developed with scalability built within 
the system. This chapter has demonstrated that the immobilisation technique was effective 
in a stirred tank micro-bioreactor platform and it exhibited a number of additional 
functional and process benefits.  
Functionality of immobilised GM-CSF was retained in an agitated stirred tank culture system 
at relatively high stir speeds (350 rpm). Maximal functional responses were achieved in 
agitated culture systems at a stir speed of 350rpm (or ~70 cm/s). This suggests a very short 
interaction time between GF and receptor is required for a functional response. A response 
time of 50 ms is reported for enzyme-substrate interactions and blood flow in the human 
body can reach a velocity of 40 m/s within the aorta [118] [114]. Therefore, signalling 
cascades can be induced with brief interactions between ligands and receptors.  
The ability for the GF immobilisation technique to retain maximal biological responses in 
stirred tanks bioreactors means the immobilisation method can be scaled with respect to 
surface area to volume ratio. 
This chapter has highlighted the need to tailor PEG molar concentrations for individual 
growth factors in order to achieve maximum surface concentration. Three growth factors 
were immobilised, surface concentration optimised and shown to retain biological function. 
The ability to manipulate surface concentrations may be important for phenotype 
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maintenance of to induce cell differentiation by tightly controlling the ratio of growth factor 
combinations or total concentrations [119]. The activity of certain growth factors may be 
absent at low surface concentrations. A limitation of the immobilisation method is that the 
orientation of the GF cannot be controlled during immobilisation and it is expected that 
some of the GF will be inactive in its immobilised form, reducing the efficacy of the 
immobilisation method. Furthermore, the availability of lysine residues for Biotinylation of 
each individual GF should be given more consideration, in order to effectively titrate PEG 
molar ratios for optimal surface immobilisation.  
Particle loss represents a major challenge for sustained and controlled functional responses 
particularly following media changes and frequent sampling – the sensitivity to particle 
concentration has been shown in a previous chapter. The use of strong magnets (see  2.9.3), 
slow removal of supernatant and reduced sampling frequencies however can overcome this 
issue and was shown to be effective for sustained cell growth.  
Remarkably, iGM-CSF has been shown to retain consistent functionality following 192 hours 
of culture, whereas soluble GM-CSF can decrease as much as 50% over the course of 72 
hours. Therefore the immobilisation method not only provides a method to recycle the 
growth factors, but the method also seemingly improves the stability of the growth factors 
which is in line with the reported literature[120], [121]. Increasing the stability of growth 
factors by immobilisation, together with the ability to recycle the growth factors following a 
media passage has the potential to greatly reduce the quantities required (and therefore 
costs) for cell and gene therapy manufacturing processes.  
In this chapter a transient exposure to iGM-CSF, as little as 30 minutes, has been shown to 
provide a lasting functional response (over 20 hours). In addition, continuous exposure to 
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growth factors can be detrimental to cell signalling as it may lead to receptor down-
regulation and desensitization.  
A manufacturing system consisting of transient exposure would increase the number of 
manipulations in the manufacturing process. Various methods have been tested within this 
thesis to remove immobilised growth factors from culture and the methods are listed below 
with an explanation as to why they would or wouldn’t be scalable in stirred tank 
bioreactors: 
1. External magnet on the vessel wall 
• The immobilised growth factors would be drawn to the side of the vessel 
causing a ‘mound’ of particles. This would increase the shear stress that the 
cells were exposed to (particularly if the system remained agitated during 
particle removal). Furthermore, the risk of particle aggregation is increased, 
depending on the length of time the particles are held for. 
2. A magnet in contact with the media supernatant 
• This process would entail the process being open, meaning it would have to 
take place in a Grade A clean room environment – increasing costs. Magnets 
would have to be sterilized prior to use if not disposable, the sterilization 
process would need to be validated and particles would not be reusable since 
they would be stuck to the magnet. 
Clearly the two processes presented above would over complicate the process and the 
benefits of immobilised growth factors would be outweighed by the complexity.  
Ideally the manufacturing system would consist of a disposable bioreactor and would be a 
‘closed’ process. Therefore the Dynamag™ CTS magnet system could be applied to the 
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process where the product is drawn through tubing which is wrapped around a magnet, 
removing the particles and eventually the product is transferred into a secondary bag or 
vessel by gravity ( Figure 47). The wrap-around magnet could be used in a scalable stirred 
tank bioreactor system which would be a simple, closed processing method to withdraw 
immobilised growth factors from the process.  
Additional functional benefits have been demonstrated here, where iGFs have been shown 
to amplify functional responses and prolonged responses are achieved in comparison to 
soluble GFs. These functional benefits are likely achieved by assisting cytoskeletal changes 
via a physical anchor point and enhancing receptor clustering [85], [122], [123].  
 
 Figure 47. The Dynamag™ CTS magnet for removal of T-cell activation beads. A) The set up shows the 
product is transferred from its primary bag to a secondary bag via primary and secondary magnets 
in a closed system in order to remove particles from the cell suspension B) A close-up of the 
secondary magnet which the set-up could be transferred to a large scale bioreactor. 
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5 Application of Immobilisation Technology in a Primary 
Cell Culture System 
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5.1 Introduction 
The previous results chapters have shown the successful development of a novel growth 
factor technology which was demonstrated using a model haematopoietic growth factor, 
GM-CSF and functionality was shown in a GM-CSF dependant cell line, TF-1.  
The general introduction discussed the market for expansion of umbilical cord blood derived 
HSCs - since the majority of banked cord blood units do not contain enough cells to treat an 
adult patient. This section will evaluate the technologies reported for the expansion of UCB 
derived HSCs and growth factors which are fundamental for stem cell maintenance and 
expansion.  
CD34+ cells derived from umbilical cord blood has added benefits over CD34+ cells derived 
from other sources such as bone marrow and peripheral blood. Some of the benefits are 
listed below: 
• Lower incidence of GvHD – Higher HLA disparity results in lower incidence of GvHD 
in comparison with HSCs from other sources [124].   
• Wider availability and readily available – umbilical cord blood is readily available, 
albeit specialist nurses are required to collect the material. 
• Improved engraftment – increased long term repopulating stem cells (LT-HSC) [125]. 
• Non-invasive donation 
Despite the many advantages of umbilical cord derived HSCs, low CD34+ percentages from 
the tissue means not enough cells are present for good clinical outcome for adult patients. 
1x109 total nucleated cells is often regarded as a minimum number of cells for transplant by 
the field[126]. This is the reason why current utilisation rates banked cord blood is only 1-3% 
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and declining. It is clear that there is a clinical requirement and commercial market for the 
expansion of CD34+ cells derived from umbilical cord blood.  
Much research has been undertaken to increase the utilisation of cord blood for transplants. 
Research has involved the investigation of non-related cord blood transplants, double cord 
blood unit transplants and ex vivo expansion of cord blood units.  Table 7 gives an overview 
of current ex vivo expansion technologies.  
 CD34+ Expansion Technologies Table 10.
Technology  Description 
Copper Chelator [127] Removal of intracellular copper which 
regulates HSC self-renewal and 
differentiation[128]. 
Notch [51], [86], [129] Notch signalling has developmental roles 
and increases transcription of genes 
required for HSC expansion [130].  
Perfusion [45], [93] Dilution of inhibitory factors, consistent 
supplementation of growth factors and 
glucose.  
Nicotinamide[131] Inhibition of a SIRT1 deacetylase enhances 
proliferation potential of HPCs with 
decreased dependency on growth factors 
and increases telomerase activity via 
catalytic subunit of telomerase, hTERT [132]. 
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Aryl Hydrocarbon receptor antagonist [133] Inhibits receptor involved in regulating 
haematopoiesis[134]. 
 
Immobilised Notch with a defined soluble growth factor cocktail (SCF, TPO, Flt-3L) has 
shown some of the most promising results in the clinic and highlights the importance of 
immobilised ligands to recapitulate the stem cell niche and improve the expansion of HSCs 
ex vivo[86], [135].  
Growth factors remain an essential supplement for the maintenance and expansion of 
CD34+ cells. An array of growth factors have been reported in the literature for 
haematopoietic cell culture summarised in  Table 8. The table highlights no consensus on the 
growth factors and or concentrations of growth factors used for the culture of CD34+ cells, 
however it is clear that three or four growth factors (SCF, TPO, Flt-3L, Il-3) are commonly 
used in expansion protocols and are important for CD34 maintenance and expansion.  
Highly cited CD34+ expansion journal publications routinely use SCF, TPO, Flt-3L and IL-3 
[51], [129], [136], [137]. This chapter will focus on the immobilisation of three growth 
factors; SCF, TPO and Flt-3L for the expansion of UCB derived CD34+ cells.  
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 Haematopoietic growth factors, their effects on cell lineages and applied concentrations.  Table 11.
Cytokine Effect on blood lineage Applied Concentrations 
SCF Prevents HSC apoptosis[138]. 
HSC self-renewal[139].  
10-100 ng/mL [140] [141] [142] [143] [144] [145] [146] 
EPO Directs erythrocyte lineage. 28 ng/mL[142]; 
3-5 IU/mL[147] [144] [26 
TPO Regulates megakaryocyte and platelet development[148]. 
HSC Self-renewal[148][149]. 
HSC Expansion[148]. 
10-50 ng/mL [143][146][141] 
IL-3 Regulates proliferation of HSCs[150].  
Reduces in vivo reconstitution potential [151].   
5-100 ng/mL [141][144][145] 
[147][142] 
IL-6 Directs differentiation to mature lymphocytes.  
Increases proliferation of HSCs [152].  
10-50 ng/mL[145][140][142] 
 
  
IL-11 Regulates multi-lineage and committed progenitors[153]. 
Progresses cell cycle.  
 50 ng/mL [154] 
Flt-3L Regulates proliferation and differentiation of HSC progenitors 
[155][156].   
10-50 ng/mL[144][145][141] 
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G-CSF Proliferation and differentiation of Granulocytes. 
HSC mobilization.  
100 ng/mL[142][145][144][157]  
GM-CSF Proliferation and growth of granulocytes and monocytes. 
Mobilisation of HSCs into the peripheral blood.  
2-20 ng/mL[142][144][145] 
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The presentation mode of growth factors (soluble, membrane bound or immobilised) can 
have an impact on signalling fluxes and consequently impacts cell fate [120], [158], [159]. 
Fusion of unrelated growth factor molecules has shown the pleotropic and synergistic 
actions of growth factors in close proximity which influences downstream signalling and 
leading to increased mitogenic responses [160]. 
This chapter aims to investigate the immobilisation of multiple, clinically relevant growth 
factors, both individually and co-presented in a way that recapitulates the stem cell niche. In 
a proof of concept primary cell system, the growth factor immobilisation technology will be 
demonstrated in a clinically relevant system – the expansion of umbilical cord derived 
haematopoietic stem cells.  
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5.2 Results 
Three growth factors (SCF, TPO, Flt-3L) were targeted for the expansion of UCB derived HSCs 
as discussed in the introduction to this chapter. This section follows the strategy developed 
in the previous two chapters, where the functionality of the immobilised growth factors was 
demonstrated in a growth factor dependent cell line and surface concentration maximised.  
A switch from the TF-1 cell line to an m-07e cell line was made, because the m-07e cell line 
is dependent on multiple growth factors that will be investigated in this chapter. Finally, the 
iGF method will be applied to a system for the expansion of UCB derived HSC. 
5.2.1 Functional Response of Immobilised and Soluble Growth Factors in M-07e Cell Line 
A dose-response profile of individual soluble growth factors (SCF, TPO, and GM-CSF) was 
generated to determine the working concentrations of soluble growth factors to compare 
with the functional response of immobilised growth factors.  Figure 48 shows the dose-
response profiles of soluble SCF, TPO and GM-CSF in the m-07e cell line. Maximum response 
was achieved with 100, 100 and 10 ng/mL of SCF, TPO and GM-CSF respectively. SCF 
induced cell proliferation most prominently out of the three growth factors investigated, 
however much higher concentrations of SCF (10 fold increase) were required for the 
maximal response in comparison to GM-CSF. As summarised in  Table 8, the role of SCF is 
primarily for maintenance and proliferation of stem and progenitor cells, whereas GM-CSF 
and TPO have roles in directing cell differentiation and proliferation of stem cells to a lesser 
extent. 
To determine the functional activity of additional clinically relevant growth factors, SCF, TPO 
and GM-CSF were immobilised and cultured in an M-07e functional assay.  Figure 49 shows 
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that in addition to GM-CSF, SCF and TPO remain functionally active once immobilised using 
the streptavidin immobilisation technique. GM-CSF and TPO both significantly exceeded the 
maximum sGF response (P = <0.0001) whereas SCF did not achieve the soluble response 
despite reaching the top of a dose-response response curve. Maximum responses were 
achieved with 2.32x104 particles/mL (1.4 fg/particle) for GM-CSF, 2.65x104 particles/mL for 
TPO, and 8.42x106 particles/mL (1.9 fg/particle) for SCF. Negative effects on cell viability 
were observed for highest concentrations of GM-CSF and TPO (>5.35x104 and >8.82x104 
particles/mL respectively). This could be due to receptor down-regulation and or de-
sensitization at high iGF concentrations as reported in the literature [115], [116]. In this cell 
line 0.003 ng/mL of iGM-CSF was required to accomplish the maximum soluble response 
achieved using 10 ng/mL of sGM-CSF, providing a similar orders of magnitude potency gain 
to that observed in the TF-1 line. Additionally, 16 ng/mL of iSCF accomplished 65% of the 
maximum response achieved with 200 ng/mL of sSCF. This is consistent with literature 
indicating distinct roles for soluble and bound SCF[161], [162]. 
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 Figure 48. Soluble dose-response assays of SCF, GM-CSF and TPO in a cell proliferation assay using a 
factor dependent cell line, M-07e. Maximum response was achieved with 100, 10 and 100 ng/mL of 
SCF, GM-CSF and TPO respectively. Response was measured using an AlamarBlue assay. Data points 
represent mean fluorescent intensity (n=3±S.D). 
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 Figure 49. Functionality and dose response of immobilized GM-CSF, SCF and TPO. The function and dose-
response of three immobilized growth factors were investigated in a multi-factor dependent cell 
line (M-07e). All three factors remain biologically active once immobilized. Immobilized GM-CSF 
and TPO both significantly exceed the maximal soluble response whereas SCF did not achieve the 
maximal soluble response. Where quantified, data points are labelled with total quantity of 
immobilized growth factor (n = 3 ± S.D.). * P = 0.01–0.05, **P = 0.001–0.01, ***P = 0.0001–0.001. 
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5.2.2 Immobilisation Preferences of Growth Factors 
The complex nature of the HSC niche was described in the introduction. A combination of 
extracellular matrix, integrins and immobilised growth factors and other ligands make up 
the niche and are responsible for both phenotypic maintenance and homing of stem cells 
[39]–[41]. It was hypothesised that the immobilisation method developed here could be 
used to create microenvironments presenting multiple growth factors and therefore 
recapitulating the stem cell niche in a scalable culture system.   
It was hypothesised that the binding preferences of multiple biotinylated GFs incubated 
with particles at equivalent concentrations would be correlated to lysine content of each 
growth factor.  Figure 50A shows the binding preferences of GFs mixed at equal 
concentrations in pairs or in a combination of three growth factors. The growth factors were 
shown to preferentially immobilise in the following order of preference SCF>GM-CSF>TPO.  
In concurrence with the hypothesis - GF binding preferences were correlated with GF lysine 
content ( Figure 50B), where higher lysine number increases binding preference and total GF 
bound ( Figure 50C). Co-presentation of multiple GFs could be controlled by compensating 
for lysine content, representing another method for controlling surface concentration of 
iGFs. 
Notably, total bound GF was low in all cases in comparison to singly bound growth factors in 
previous experiments this is likely due to increased concentrations of non-reacted PEG 
which competitively binds for the biotinylated GFs. Purification of biotinylated growth 
factors following Biotinylation could overcome this issue, but adds further costs and 
processing steps to the immobilisation technique. However, synergistic effects of co-
presentation of iGFs may compensate for lower surface concentrations.  
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 Figure 50. The immobilization preferences for a mixture of two or more growth factors at equal molar 
concentrations were investigated. (A) The preference for immobilization was SCF>GM-CSF>TPO 
from high to low (B) Binding preference was linked to the residual lysine number of the growth 
factor (C) A linear relationship between lysine number and concentration of immobilized GF was 
shown (n = 3). 
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5.2.3 Expansion of CD34+ Cells using Immobilised SCF 
SCF is a key growth factor for the expansion of CD34+ for its role in cell cycle progression 
[163]. In this final section, immobilised SCF was used to expand UCB derived HSCs as proof 
of concept in a primary cell culture system.  
 Expansion of Cryopreserved CD34+ UCB derived HSCs were incubated with iSCF to 
determine if CD34+ cells could be expanded in static culture following incubation for 72 
hours.  Figure 51 shows the response of CD34+ cells following 72 hours incubation with 
soluble or immobilised SCF. Approximately 0.7 population doublings per day were achieved 
with the highest concentration of soluble SCF (100 ng/mL) whereas no cell expansion was 
observed in all immobilised conditions.  
Quantification of iSCF showed immobilisation of 0.72 femtograms per particle. Total 
concentrations of the immobilised SCF conditions were 108.7, 36.2, 3.6 picograms of SCF for 
1.5x105 , 5.0x104 and 5.0x103 particles per mL respectively. Total concentrations are 
relatively low in comparison to soluble SCF and therefore higher concentrations may be 
required. Previously we have seen 10 fold less GM-CSF quantities used in comparison to SCF. 
Furthermore, CD34+ cells were cryopreserved prior to experiment meaning cell growth was 
sub-optimal. To reduce the complexities of cryopreservation the experiment should be 
conducted on fresh CD34+ cells.   
 Figure 55 shows representative pictomicrographs of cells incubated with soluble or 
immobilised SCF where cell morphology for iSCF conditions looked consistent with high 
concentrations of soluble SCF. In addition, phenotypic analysis ( Figure 51) showed small 
quantities of iSCF can maintain stem cell phenotype comparable to high levels of sSCF. 
Example flow cytometry plots are shown in  Figure 52 and  Figure 53 for CD34 cells incubated 
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with soluble and immobilised SCF respectively. Positive and negative gates were determined 
using a non-stained CD34 sample ( Figure 54). 
Flow cytometry plots ( Figure 53) show distinct population of cells when incubated with iSCF 
suggesting that there may be some degree of bead internalisation. Although, particles are 
widely regarded as being non-toxic and biocompatible it is important to understand the 
nature of internalisation, since this could pose a safety concern and affect regulatory 
approval [164]. It is also important to understand the effect of internalisation on the ability 
to recycle the particles during media passages.  
The previous experiment was repeated using fresh, non-cryopreserved CD34+ cells and to 
incubate the cells with higher concentrations of iSCF since CD34+ cells require high 
concentrations (100 ng/mL soluble SCF) for maximal response.  
 Figure 56 shows the growth curve of CD34+ cells over a period of 96 hours when incubated 
with soluble or immobilised SCF. Cell growth improved from 0.6 population doublings in the 
previous experiment (with cryopreserved cells) to almost 4 population doublings at 96 hours 
with fresh non-cryopreserved CD34+ cells. This improved growth rate could be due to donor 
variability, but is likely due to un-optimised cryopreservation conditions. iSCF (140 and 70 
ng/mL) saw the fastest cell growth at 24 hours in comparison to soluble SCF, where the 
growth rate decreased following 24 hours where all conditions began to merge.  Decreased 
cell growth following 24 hours is likely due to a media exchange requirement (i.e. 
supplementation of glucose due to rapid cell expansion). 
Quantification of iSCF particles showed 14.1 femtograms of immobilised SCF per particle. 
This surface concentration is one of the highest immobilisation surface concentrations 
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achieved with the immobilisation technology and iSCF was supplemented in excess, 
therefore the functional response could have been saturated at these levels.  
Stem cell phenotype did not significantly change between SCF conditions – around 10% of 
total cells were CD34+ CD133+ for all conditions at 96 hours of culture. 
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 Figure 51. Expansion and phenotype of cryopreserved CD34+ cells with low concentrations of iSCF. No 
expansion of CD34+ cells was achieved with iSCF however stem cell phenotype was maintained in 
conjunction with high levels of sSCF (n=3 ±S.D).  
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 Figure 52. Exemplar flow cytometry plots and gating strategy for CD34+ cells incubated with soluble SCF 
at 100 ng/mL concentration.  
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 Figure 53. Exemplar flow cytometry plots and gating strategy for CD34+ cells incubated with immobilised 
SCF at 5x105 particles per mL.  
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 Figure 54. Example of a non-stained CD34 sample used to gate negative and positive samples.  
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 Figure 55. Representative photomicrographs of CD34+ cells cultured with various concentrations of 
soluble or immobilised SCF (40x magnification). Increasing cell densities are observed with 
increasing concentrations of soluble of immobilised SCF, where differentiated cell morphology is 
observed with low concentrations or no SCF.   
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 Figure 56. Growth curve of non-cryopreserved CD34+ cells and phenotype (at 96 hours) with high 
concentrations of iSCF. 4 population doublings were achieved over 96 hours with iSCF inducing the 
fastest cell growth at 24 hours (n=3±SD). 
5.2.4 Particle Internalisation 
In both to the CD34 expansion experiments, it was observed that there was a distinct 
population of cells when incubated with iSCF. The distinct population of cells were in 
parallel to the particle population on the y axis of FSC vs. SSC dot plots. This lead to the 
hypothesis that the particles could be internalised by CD34+ cells or it could be that the 
particles are bound tightly to the SCF receptor.  Furthermore, particle internalisation or 
membrane binding could be unique to SCF and therefore other growth factors should be 
investigated. 
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To determine if particles were being internalised or membrane-bound, CD34+ cells were 
incubated with iSCF, iTPO and iFlt-3L for 72 hours or 30 seconds before analysis using flow 
cytometry with the hypothesis that if the distinct populations were not present following 30 
seconds of incubation with iGFs then bead internalisation is likely.  
 Figure 57 shows the dot plots of CD34+ cells following incubation with three iGFs and an 
untreated control. The flow cytometry plots show distinct cell populations were present in 
both the 72 hour and 30 second incubation conditions for all three immobilised growth 
factors.  
Internalisation of particles following 30 seconds of incubation is unlikely; the rate of 
endocytosis is typically in the range of minutes to hours [165]–[167]. Therefore it is likely 
that the particles bind tightly to the cell membrane of CD34+ cells.  
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 Figure 57. Flow cytometry dot plots showing unique populations of CD34+ cells incubated with iSCF for 
30 seconds or 72 hours. Unique populations were present at both time points suggesting that 
particles were adhered to the cell surface membrane as opposed to being internalised.  
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5.3 Discussion 
Cell and gene therapies require defined combinations of growth factors for maintenance, 
expansion or for directed differentiation of stem cell and progenitor cells. The importance of 
co-presentation of growth factors has been reported in the literature [85]. Furthermore, co-
presentation is seen in the stem cell niche which is linked to stem cell maintenance and or 
stem cell homing to the niche.  
This chapter aimed to investigate immobilisation of multiple clinically relevant growth (SCF, 
TPO and Flt-3L) factors in a model, scalable culture system for the expansion of UCB derived 
HSCs. SCF, TPO and Flt-3L are commonly used in HSC expansion protocols and are known to 
have roles in stem cell maintenance and or proliferation [168]. SCF, TPO and Flt-3L were 
shown to retain functionality after immobilisation, demonstrating that the immobilisation 
technique is universally applicable for a variety of haematopoietic growth factors.  Whilst 
SCF was shown to have a reduced biological response in comparison to the soluble 
equivalent, it may be that immobilised SCF role is restricted to phenotypic maintenance 
when immobilised, by influencing downstream signalling[120], [159], [169]. Therefore a 
balance between proliferation and cell phenotype may need to be considered.  
Co-presentation of multiple iGFs on a single particle was demonstrated where certain 
growth factors bound preferentially over others. Binding preferences were later shown to 
be correlated with the number of residual lysine amino acids in the proteins amino acid 
sequence. This finding allows the surface concentration of multiple GFs to be manipulated 
by compensating for lysine number. This method for manipulating surface concentration 
could be used in conjunction with other methods described in previous chapters (i.e. PEG 
pg. 153 
 
molar excess) in order to fine tune the presentation of growth factors depending on the 
desired cell phenotype/dose.  
Immobilising multiple GFs has highlighted a limitation of the immobilisation technique – in 
that unreacted biotin competitively binds with biotinylated GFs effectively coating the 
particles and blocking GF immobilisation. This issue is magnified when multiple GFs are 
mixed together, since more unreacted biotin molecules are present, reducing the overall 
surface concentration of immobilised GFs. To overcome this, the immobilisation reaction 
could be reversed, so that the particles are biotinylated followed by the addition of GFs 
which would immobilise via the terminal NHS group (see  Figure 58).  However, the 
immobilisation efficiency would be limited by the rate of hydrolysis of the NHS group in the 
reverse reaction[170]. Another solution would be to purify the biotinylated GFs from 
unreacted biotin in chromatography columns (following Biotinylation step of the 
immobilisation reaction) this would improve the efficiency of the immobilisation process but 
would add increased costs and time to the immobilisation process.  
This chapter has also demonstrated that particles bind tightly to the membrane of CD34+ 
cells. Membrane binding of iGFs could pose a problem when cells are required to be 
separated in from the particles for example in the envisaged manufacturing process 
(described in the succeeding chapter). However, these results were only shown in static 
cultures and it is likely that the shear stress (within a stirred tank bioreactor) would 
disengage the particles from the cell surface following brief interactions in agitated culture 
systems. This is why agitation during cell selections involving MACS particles is not 
recommended along with T-cell activation with Dynabeads™. Particles could be released 
with trypsinisation if permanent binding occurred in agitated systems, but this would be an 
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undesirable process step as this could affect the downstream cell phenotype and health and 
would also affect the function of the iGFs following release [171], [172].  
In conclusion, this chapter has demonstrated the use of multiple immobilised growth factors 
for cell culture applications. In final proof of concept experiments the technology has been 
shown suitable for the expansion of umbilical cord blood derived HSCs by immobilisation of 
SCF. Taking the findings of the current chapter and those from previous chapters, the 
immobilisation technique is applicable for the expansion of UCB derived HSCs (and other cell 
culture applications) in standard scalable stirred tank bioreactors with the potential to 
significantly reduce the costs of growth factor required throughout the culture period.  
However, this chapter has highlighted further optimisation of the immobilisation technology 
is required to improve efficiency.   
pg. 155 
 
 
 Figure 58. A schematic of the Streptavidin immobilisation method using the standard ‘forward’ method 
and proposed ‘reverse’ method which may increase NHS susceptibility to hydrolysis.  
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6 Final Discussion and Future Work 
This thesis set out to address the issues associated with the use of soluble growth factors 
used in the manufacture of cell and gene therapies. High costs and lack of cellular 
phenotypic controls are some of the issues involved in the use of soluble growth factors.  
The experimental results in this thesis have shown that immobilised growth factors can 
replace soluble growth factors in scalable cell manufacturing processes. They have shown 
increased potency and distinct functional effects (i.e. increased signalling times) in 
comparison to their soluble equivalents. Being tethered to magnetic particles has allowed 
the growth factors to be manipulated independently from the media bulk and thus recycled 
during media changes. Remarkably it was shown that using immobilised growth factors - as 
little as 1.5% of the soluble growth factor requirements were required in an example culture 
system over a 192 hour experiment.  
The need to produce high doses of HSCs and the consequent need for scalable 
manufacturing systems was highlighted as early as the 1980’s where protocols to expand 
HSCs in 5L stirred tank bioreactors were described[173]. In this protocol a combination of six 
growth factors were used with four media passages which equated to over £4000 worth of 
growth factor for a single product assuming a cost of 15.4 pence per nanogram of growth 
factor (see  Table 9). If we take the results from this thesis that approximately 1.5% of the 
total soluble growth factor is required then for this particular protocol the costs of growth 
factor would have been reduced to ~£60. This could be further decreased with a 
manufacturing process that involves transient exposure. 
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 Comparison of growth factor costs in an example stirred tank manufacturing process as described by Collins et. Al, 1998 and potential costs savings using immobilised Table 12.
growth factors, assuming 1.5% of the total soluble growth factor is required [173].  
Soluble growth factor process 
     
       Total Volume (L) GF GF Conc (ng/mL) Total GF (ng/mL) Number of media 
exchanges 
Total GF 
over culture 
period (ng) 
Total cost 
(£) 
5 IL-3 5 2.50E+04 4 1.00E+05 154 
5 IL-6 50 2.50E+05 4 1.00E+06 1540 
5 SCF 50 2.50E+05 4 1.00E+06 1540 
5 GM-CSF 2 1.00E+04 4 4.00E+04 61.6 
5 G-CSF 1.5 7.50E+03 4 3.00E+04 46.2 
5 EPO 28 1.40E+05 4 5.60E+05 862.4 
       
      
4204.2 
      
Immobilised growth factor process 
     
       
      
63.063 
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HSCs have been reported to be sensitive to the shear stress in agitated systems and CD 
marker expression can be altered[168], [174]. Such culture conditions were most likely 
optimised for cell expansion and not phenotypic maintenance. Simple DoE experiments 
could be conducted to elucidate the optimal agitation conditions required to achieve a 
balance between the desired phenotype and level of cell expansion required. Furthermore, 
it would be interesting to compare the effects of soluble and immobilised growth factors in 
agitated systems and their effects on phenotypic maintenance since it is reported that 
immobilised growth factors can improve control of cell phenotype[175].  
The lack of on-line monitoring tools in scalable cell therapy manufacturing platforms 
(particularly) has been identified as a major problem for the field going forward[45], [94]. 
Effective media feeding strategies that maintain consistent levels of media supplements and 
reduce the inhibitory paracrine signalling factors or toxic metabolic by-products is necessary 
for the production of consistent cell based products with good viability and the desirable 
phenotypic profile and also reduced the waste associated with over-supplementation in 
standard batch-feeding regimes. Strategies to monitor cytokine levels on-line in perfusion 
systems have been described with the ability to automatically adjust media feeding rates to 
maintain consistent levels of cytokines[93]. Such systems are likely to require significant 
modifications to standard culture platforms and will require significant development of 
equipment and algorithms for individual culture protocols. In this thesis, the growth factor 
immobilisation method was shown to maintain stability up to 192 hours which negates the 
need for such on-line measurement systems and highlights that the technology is 
transferrable to standard agitated systems without further modifications.  
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Despite the promising results, there is further work and questions relating to the 
immobilisation method that should be addressed in future work. In the selected 
immobilisation method, the orientation of the immobilised protein cannot be controlled. 
Incorrect orientation could mean that the growth factors epitope is not accessible to the 
receptor and therefore is essentially inactive. However, experimental results have shown 
that the immobilised growth factors are more potent than soluble, despite a proportion of 
the growth factors being immobilised in the incorrect orientation. Therefore this is not 
problematic from a functional point of view, but it does decrease the manufacturing efficacy.  
Additionally, Immobilisation efficiencies are further decreased because biotinylated growth 
factors are not purified from non-biotinylated growth factors after the initial PEGylation 
stage. The result is that non-reacted PEG molecules competitively bind for pegylated growth 
factors. A solution to this could be to introduce molecular weight cut off chromatography 
columns to separate PEGylated proteins from unreacted PEG molecules. However, the 
recovery of protein is likely to be impacted and this would add further processing steps 
which increases manufacturing times, cost and may introduce further variability into the 
process.  
The PEGylation site within growth factors could affect the proteins activity and or 
folding[176]. Although generally lysine residues are not involved in the folding of the 
tertiary structure, such amino acid groups in proximity to the active site or binding domain 
could significantly affect the proteins activity. Furthermore, PEG molecules bind 2-3 water 
molecules per subunit, meaning PEGylated proteins effectively swell in size and can 
significantly impact spatial presentation and steric hindrance[176]. No impact was seen 
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from PEGylating any of the growth factors investigated in this thesis however it is important 
to note some proteins may not be suitable for the immobilisation method.  
Edman degradation is a technique which could be employed to investigate the common 
sites for conjugation however this is usually only amenable to small peptides[177]. MALDI-
TOF Mass Spectroscopy may be more suited to determine the site and degree of PEGylation 
per growth factor molecule. Whilst X-ray laser diffraction could be employed to determine 
the protein structure differences before and after PEGylation.  
The rationale for incorporating a PEG linker within the conjugation bond was to enable the 
spatial presentation of different growth factor molecules to be tailored depending on 1) 
their required surface concentration and 2) molecular weight to prevent steric hindrance. 
The schematic shown in  Figure 59 shows how tailoring PEG linker lengths to growth factors 
has the potential to control surface concentrations and spatial presentation to enable 
receptor binding. The schematic also shows how PEG length will be a balance between 
optimal surface concentration and correct spatial presentation to allow growth factor – 
receptor binding particularly in relation to the growth factor size. A simple screening 
experiment using a functional assay could be used to investigate the effects of PEG length 
on the functional activity of individual growth factors.  
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 Figure 59. The effect of PEG length on spatial presentation and surface concentration of immobilised 
growth factors. A) Shows that at a fixed surface concentration smaller PEG molecules will cause 
steric hindrance between growth factor and receptor binding and by increasing peg length the 
spatial presentation is optimised allowing binding and cell signalling B) For larger growth factor 
molecules, a larger PEG length may increase surface concentration of immobilised growth factor 
and smaller PEG lengths will limit surface concentration by steric hindrance.  
 
In addition to the growth factors highlighted in this thesis that are fundamental for HSC 
expansion (SCF, TPO, Flt-3l) immobilisation of delta-1 ligand (notch) has been shown to 
successfully expand HSCs[51], [86]. Immobilising a combination of such growth factors and 
notch ligands has the potential to recapitulate the stem cell niche – maintaining stem cell 
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phenotype throughout cell expansion. Combinations of such factors could be introduced 
individually or co-presented on particles. It is easy to envisage the multiple applications of 
the immobilisation technology for different cell manufacturing processes. For example, 
immobilisation of VCAM-1 and ICAM-4 adhesion molecules could recapitulate the 
erythroblast islands in vitro which are fundamental for enucleation in the process of 
erythropoiesis[178], [179].  
To conclude, the novel growth factor immobilisation method described herein has 
demonstrated many functional, financial and process benefits in comparison to standard 
soluble growth factors routinely used in cell therapy manufacturing processes. The unique 
immobilisation chemistry can be tailored to individual growth factors (and combinations of 
growth factors) in order to optimise surface concentration and spatial presentation for the 
desired functional effects. Once immobilised onto the particles, they can be manipulated 
with external magnetic fields, allowing temporal exposure and recycling of the growth 
factors which otherwise would be (almost) impossible with soluble growth factors. 
Immobilised growth factors were shown to be significantly more potent and stable and can 
increase the duration of downstream signalling responses with transient exposure. Overall, 
the immobilisation method has the potential to be transferred to all scalable cell therapy 
manufacturing protocols and may have significant impact by reducing cost and improving 
process control.  
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8 Appendix A – Optimisation of AlamarBlue Assay 
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8.1 Introduction 
AlamarBlue assay is a non-toxic cell viability colourimetric assay, commonly used in dose-
response assays. It is recommended that the culture conditions for the AlamarBlue assay are 
optimised. This section investigates cell seeding density, absorbance and fluorescence read-
out, assay incubation time, and phenol red interference.  
8.2 Results and Conclusions 
 
 Figure 60 shows the correlation between cell concentration and fluorescence intensity was 
highest  with a four hour AlamarBlue incubation period (R2 = 0.96). Correlation was at 0 
hours and 48 hours where cell growth was limiting and AlamarBlue concentration was 
limiting respectively. In contrast, the optimal incubation period was one hour for an 
absorbance read-out (R2 = 0.91). Sensitivity between cell concentrations was higher for 
fluorescence read-out in comparison to absorbance.  
 Figure 62 shows GM-CSF dose-response curves with and without phenol red media.  
Standard deviations were lower with phenol red media; however a sigmoidal relationship 
was achieved with phenol red free media and an increase in sensitivity was achieved for 
lower cell concentrations with phenol red free media.  
The culture conditions taken forward for the AlamarBlue assay were; an incubation period 
of 4 hours, a read-out using fluorescence and phenol red free media to reduce interference.  
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 Figure 60. AlamarBlue assay read-out using Fluorescence. The effect of assay incubation time and cell 
concentration on fluorescence intensity. Data points show mean fluorescence intensity (n=3±S.D).  
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 Figure 61. AlamarBlue assay read-out using Absorbance. The effect of assay incubation time and cell 
concentration on optical density. Data points show mean optical density (n=3±S.D).  
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 Figure 62. A GM-CSF dose-response assay in a GM-CSF dependent cell line, TF-1, using an AlamarBlue 
assay. A) Phenol red media B) phenol red free media. Data points show mean fluorescence intensity 
(n=3±S.D).  
